CA2230557A1 - Interactive molecular conjugates - Google Patents

Interactive molecular conjugates Download PDF

Info

Publication number
CA2230557A1
CA2230557A1 CA002230557A CA2230557A CA2230557A1 CA 2230557 A1 CA2230557 A1 CA 2230557A1 CA 002230557 A CA002230557 A CA 002230557A CA 2230557 A CA2230557 A CA 2230557A CA 2230557 A1 CA2230557 A1 CA 2230557A1
Authority
CA
Canada
Prior art keywords
affinity
binding
target
stimulus responsive
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002230557A
Other languages
French (fr)
Inventor
Allan S. Hoffman
Patrick S. Stayton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2230557A1 publication Critical patent/CA2230557A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals

Abstract

The combination of the capabilities of stimuli-responsive components such as polymers and interactive molecules to form site-specific conjugates which are useful in a variety of assays, separations, processing, and other uses is disclosed. The polymer chain conformation and volume can be manipulated through alteration in pH, temperature, light, or other stimuli. The interactive molecules can be biomolecules like proteins or peptides, such as antibodies, receptors, or enzymes, polysaccharides or glycoproteins which specifically bind to ligands, or nucleic acids such as antisense, ribozymes, and aptamers, or ligands for organic or inorganic molecules in the environment or manufacturing processes. The stimuli-responsive polymers are coupled to the recognition biomolecules at a specific site so that the polymer can be manipulated by stimulation to alter ligand-biomolecule binding at an adjacent binding site, for example, the biotin binding site of streptavidin, the antigen-binding site of an antibody or the active, substrate-binding site of an enzyme. Binding may be completely blocked (i.e., the conjugate acts as an on-off switch) or partially blocked (i.e., the conjugate acts as a rheostat to partially block binding or to block binding only of larger ligands). Once a ligand is bound, it may also be ejected from the binding site by stimulating one (or more) conjugated polymers to cause ejection of the ligand and whatever is attached to it. Alternatively, selective partitioning, phase separation or precipitation of the polymer-conjugated biomolecule can be achieved through exposure of the stimulus-responsive component to an appropriate environmental stimulus.

Description

CA 02230~7 1998-02-26 WO 97/09068 ~ PCT/US96/13874 INTERACTIVE MOLECULAR CONJUGATES

Background of the Invention This application claims priority to U.S. Serial No. 60/003,148 filed September 1, 1995 by Allan S. Hoffman and Patrick S. Stayton.
5This application is generally in the area of molecular conjugates for use in affinity s~;~aldLions, drug delivery, sensors and other bioen~i~.Pe, illg applications.
There are many technologies, e.g. separations and sensors, which utilize a molecular recognition step as a key device component. These 10 molecular recognition steps can be mP~ tP~ by biomolecules or by synthetic receptors. Biological recognition processes have also been widely ntili7P-l in many clinical, industrial and labolatc,ly applications, inrlll-ling biost;~alalions, cell culture, r1i~gnc,stirs, biose.lsol~" L~ ed drug delivery, and el~yllle and cell bioprocesses. They also have 15 hllpolL~llL new and potential uses in drug discovery, fimll~mPnt~l lcseal-;h in biological scienrPs and hlfollll~llion processing. The central event in the recognition process involves the hlL~ .cLion or specific billlillg belwc;ell a r~ce~Lul and a ligand, such as the antibody-antigen binding reaction, or en_yme-substrate binding step, which is notable for its 20 exceptional colllbillation of specificity and affinity. The ability to control this binding step could not only lead to improvement in existing technologies but could also create entirely new applications in medicine, biotechnology, and industrial proce~ing.
Protein conjugates with other molecules have long been used for 25 protection of the protein from recognition, e.g., PEGylated l~roteills, ~ L~l~eLillg purposes and in separations and diagnostics technology, for example, biotin-strepavidin reactions and antibody-mPrli~tPcl affinity chromatography and antibody-enzyme conjugates, as in ELISA. Most of these are examples of non-site-specific conjugates, such as PEGylated 30 ploLeills, antibody-drug bioconjugates and polymer-drug conjugates.
Polymers and small molecules have also been site-specifically conjugated to proteins for other purposes. For example, as reported by CA 02230~7 1998-02-26 Chilkoti, et al. (1993), a stimuli-responsive polymer was site-specifically conjugated to a genetically en~ eell,d protein in order to precisely control the polymc;I.l)loL~ill stoichiometry and to locate the polymer away from the protein active site, so that a physical phase sepaIdlion could be carried 5 out without h~ r~,lhlg with the recognition site bhldillg activity. Site-specific conjugation of polyethylene glycol to ~roteiIls via gen~tir~IIy-erl~inPered ~;y.lehle residues has also r~ceIllly been reported by Goodson and Kaktre, 1990; and Benhar, et al. 1994). These studies were cleci~ne~l to hlcI-,ase the circulation time and stability of therapeutic ~lvte"ls 10 without hIlt;~relillg with their activity, by ~ccnring that the conjugated polymer was ~tt~rll~l away from the active site. Polylysine polymers have also been conjugated to antibody fragments via existing thiol groups, in order to achieve better biodistribution and greater bioa~;Livi~y of im~ging and thela~ ic antibodies, as lepc,l~ed by Slinkin, et al. 1992.
15 Numerous examples of enginPering cy~.L~hIe residues for site-specific conjugation of small molecules, such as fluorophores or drugs, have been described by Stayton, et al. 1988). The photo~.wiLcllable binding of ligands to some protein binding sites via photochromic dye conjugation has also been le~olLed by Willner and Rubin 1992; Willner et al. 1993.
20 A photochromic dye that exists as two light-interconvertible iSOllltl~ was conjugated randomly to protein lysine amino sites. Protein activity was shown to be dependent on the state of isomerization, so the protein could be switched between active and inactive forms by the photoiso~lIe~i~dtion of the dye. Concanavalin A binding to saccharides has been controlled by 25 non-specific conjugation of several thiophenfulgide dyes to Iysine residues (Willner and Rubin, 1992). The photoregulated activity of acetylcholinesterase and chymotrypsin via photochromic enzyme inhibitors has also been demonsLIdLed by Bieth, et al. 1969.
Despite the recognition capabilities of proteins, technology based 30 on protein catalysis, separations or delivery is often burdened by materials and procecsing costs. These drawbacks are related to the need to control CA 02230~7 1998-02-26 several filn~l~m~ontal molecular processes such as protein recognition and binding to the target molecule, reaction kin~tirs, and se~dld~ion and purification of the target molecule or its reaction by-product.
Current methods for controlling the sequential binding and release 5 of target ligands in affinity-based technologies generally depend on the immobilization of the affinity agent on a solid surface, contact with a solution cont~ining the target ligand and other species, to allow specific bindil.g of the ligand to the affinity agent, and, for elution of a target ligand, the use of chtomi~ which are potential dell~Lu~ L~ and/or 10 solutions with large challges in pH or ionic ~L1G11~Lh. Processing steps are generally slow, requiring lengthy equilibration with large volumes of G~pel~i~e buffer lllixLul~S, and thus are often a primary hurdle in cost-effective separations. Non-specific binding of non-target molecules often co..~;....i.~te- the product. The need for advanced elution strategies in 15 affinity-based techniques has been noted in the liL~,ldlule. (Yarmush et al., Biotechnol. Pro~. 8: 168-178 (1992)). Similarly, biosensor technologies (e.g., environmental or biological stream analysis) employing a protein-ligand detection system require elution of the bound target to regenerate the biosensor. Current immllnc~rlcorbent, biosensor and 20 chromatographic proce~ing (e.g., elution) strategies would greatly benefit from a controlled, triggered release step providing faster response times and cleaner, purer and more concentrated separation streams.
There is a pressing need in the mP-lie~l and procçscing industries for cost-effective isolation and delivery of thela~GuLic interactive 25 molecules, rapid diagnostic strategies for preventive care, controlled and targeted delivery of therapeutic molecules, bioresponsive and biocompatible materials and careful control of enzyme-based processes.
Similarly, cost-effec~ive separations and diagnostic technologies are needed in the food, agriculture and marine industries, and for 30 environmental testing and remP~ tion.

CA 02230~7 1998-02-26 It is therefore an object of the present invention to provide materials which can be used to modulate or "switch on or off" affinity or recognition interactions beLw~en molecules. for example, biological molecules, such as receptor-ligand inter~tions, enzyme-substrate S interactions, and nucleic acid-complem~ont~ry nucleic acid intrr~rtions7 or by synthetic rec~;~Lol~ such as host-guest complexes.
It is a further object of the present invention to provide methods for making and using these materials for procescing, ph~rm~relltir~l and mr-lir~l applications, and other technologies involving molecular binding.

0 Su~ dlL,~' of the Invention The combination of the capabilities of stim~ lc-responsive COlllpollellLi and intrr~rtive molecules to form site-specific conjugates which are useful in a variety of assays, sep~r~ti~ ns, proce~ g, and other uses is disclosed. The polymers can be manipulated through alteration in 15 pH, I~;lll~e.dLult~, light, or other stimuli. The interactive molecules can be a biomolecule, such as (a) peptides or plOL~:illS, for example, antibodies, l~,cc~L~ , or enzymes, (b) polysaccharides or glycu~lvLeh.s, or (c) nucleic acids such as antisense, ribozymes, and aptamers, all of which specifically bind to ligands or receptors, or a ligand for an organic or hlol~ dl~iC
20 compound, for example, a metal rhrl~ting agent. The stimuli-lc;~o-~iv~
colll~(,ullds are coupled to the interactive molecules at a specific site so that the stimnl-lc-l~ollsive co.n~!olle..L can be manipulated to alter ligand binding at an adjacent ligand binding site, for example, the antigen-binding site of an antibody or the active site of an enzyme. Binding may 25 be completely blocked (i.e., the conjugate acts as an on-off switch) or partially blocked (i.e., the conjugate acts as a rheostat to partially block binding). Partial blocking can be used to effect selective binding, by still allowing small ligands to bind but totally blocking larger ligands.

CA 02230~7 1998-02-26 These conjugates provide precise control of molecular interactions, for example, protein recognition steps or enzyme reaction steps in the processes by external signals, which avoid undesirable illlcl~e,cllces or damage to the interactive molecules and targets during affinity binding, 5 reaction (catalysis), or "unbinding" (sc~aldlion). The interactive molecular conjugate ~.y..lclllS are easy to adapt to a wide variety of sc~alalion, ~ gnnsti-~, reaction, enzyme plocesses and delivery applications, and are economical to use.
Examples demol~.lldlc formation of a site-specific conjugate by 10 genetically en~ eling a protein, streptavidin, to insert a coupling site, then coupling a T-lc~ul.'.i~e polymer, polyNIPAAm, to the coupling site.
The physical relationship (col~o,lllalion) of the polymer to the biotin binding site of the streptavidin is controlled by altering the telll~cldlulc of the reaction; i.e., at low Lc~ dtures, 100% of the biotin is bound, at 15 higher Iclll~cl~l~ul~s, 37~C, ~ ir~ ly less biotin is bound.

I~rief Des~ ,tion of the I~dwhlF,i, Figure la is a scl~ lir illustration of a stim--h-~-responsive polymer, site-specifically conjugated to a protein, that functions as a ligand affinity switch. Figure lb is a srh~m~tir illustration of graft and 20 block copolymers and random copolymers which enh~nre the stimllillc response. Figure lc is a sçh~ ic illustration of the ligand conjugate.
Figure ld is a schlom~tir illustration of the combination of ligand-conjugate with receptor-conjugate.
Figures 2a-d are schematic illustrations of four different modes of 25 the affinity switch action of the responsive polymer-interactive molecular conjugate, with the ligand or recognition group of the ligand shown as the triangle. Unique functionalities, such as thiols, are located at selected sites within (Figures 2a and b) or near (Figure 2c) the binding pockets or at distant sites structurally coupled or that can affect ligand binding to CA 02230~7 1998-02-26 (Figure 2d) the active site. Exposure of the conjugates to an ap~ ia stimllll-c results in binding or p~Vt~ , binding, or which alters the binding site collrollllation, as in Figures 2C and 2D.
Figures 3a-c are sçh.om~tir illustrations of an externally-triggered 5 and reverse engint-ered polymer-protein conjugate ~lesi~n~rl for surface or int~ rial or two phase partitioning sepaldlions. Figure 3a shows the stimllllls-interactive polymer in an unfolded or relaxed state. Figure 3b shows the stimnlllc-interactive polymer in a collapsed form after exposure to a stimnlll~. Figure 3c shows the same conjugate but with the stimn~
10 interactive polymer in an int~orm~ t~ state between the uncollapsed or relaxed form of Figure 3a and the completely collapsed form of Figure 3b.
Figure 4 is a sçhlotn~tir illustration of the combined affinity and partitioning switches, where signal 1 (a first stimnllls) preci~i~s the 15 polymer, directing an initial selective phase or interfacial partitioning, while signal 2 (a second stiml~ ) is used to release the ligand. A similar process may be used for phase sc~ tlalion and ligand release in two liquid phase ~7y~7lellls as shown in Figure 3.
Figure 5 is a sçhrm~tir illustration of the use of a l~.~ollsiv~;-20 polymer/engineered-protein conjugate in a sepaldlions application. The support can be a conv~lllional chromatographic resin, an HPLC support, a particulate or porous support such as a mi,_,u~u,~ us membrane or hollow fiber, a bioreactor surface, or other means for immobilization. As depicted, the receptor is streptavidin having conjugated thereto a stimnlllc-25 responsive polymer and the ligand is a biotinylated proteins such as abiotinylated antibody, protein, or enzyme, which further includes a binding site for an analyte or other target molecule and a stimulus-responsive molecule which can block or allow binding upon exposure to a second, different stimllll~. The same format can be used in aqueous two-30 phase separations, where the polymer-protein conjugates are reversibly partitioned in one or the other phase, or at the interface between them.

CA 02230~7 1998-02-26 Figure 6 illustrates an immllno~ss~y format using the srim responsive polymer-interactive molecular conjugate compositions to complex the target analyte (ligand) and a second, labeled l~c~ol in solution, which may be followed by phase separation to isolate the signal S at a solid interface or in a st;pdldte liquid phase or liquid-liquid interface.
Figure 7 illu~L~ates an embodiment of the conjugated intçr~çtive molecule for the targeted delivery of drugs from a streptavidin delivery protein which is complexed both by a biotinylated-monoclonal antibody and by a biotinylated-drug. The biotinylated-drug binding sites are also 10 conjugated with stimlllll~-responsive polymer, so that when the polymer is triggered by an external stimllln~ (e.g., a light pulse) the biotinylated drug is ejected from the binding pocket and delivered to the target cell. The two polymers may be triggered by the same or by different stimuli.
Figure 8 is a schrm~tir of delivery of a stimulus-responsive 15 polymer-interactive molecular conjugate to a cell where drug is release by pH dependent cleavage of a linker to a drug.
Figures 9a-c are schrm~tirs of three general methods for physical or chrmir~i immobilization of a stimlllllc-responsive polymer-interactive molecular conjugate to a surface. In the first of the three general 20 methods, (a) the interactive molecule may first be immobilized by non-specific adsorption (e.g., ionic, hydrophobic, etc.) or by affinity binding to surface ligand groups, or by chemically-coupling it to reactive surface groups, followed later by çhrmic~l conjugation of the responsive polymer to the surface-immobilized interactive molecule, or (b) the responsive 25 polymer is first chemically-conjugated to the interactive molecule and then the conjugate is i nmobilized onto the surface by non-specific ~ adsorption, or by affinity binding to surface ligand groups, or bychrmir~lly-coupling it to reactive surface groups, or (c) by first physically-adsorbing the responsive polymer onto the surface, or 30 çhrmif~lly-coupling the responsive polymer to reactive surface groups, CA 02230~7 1998-02-26 WO 97/09068 PCT/US96~13874 followed by çhPmir~l conjugation of the interactive molecule to the surface-immobilized responsive polymer.
Figure 10 shows the relationship between the thermal depçn-1Prlre of the biotin-binding activity and the cloud point behavior of free 5 poly(NIPAAm). The activity plot represents the % change in the biotin binding activity at the lc~e~;Li~ tempe~dLu~-,s relative to 4~C (100%
bound). The cloud point behavior of the free polymer is plotted as %
change in the light absorbance from 4~C (100%) to the upper L~ e,dL~
at 37~C.
Figure 11a shows the conjugate of a responsive copolymer and an enzyme, where the responsive copolymer has pendant drug molecules conjugated to the copolymer chain backbone by linkages that are degradable by the same enzyme to which the copolymer is conjugated.
When the polymer is stim~ ted to collapse its coil, the enzyme is turned off, and it cannot release the drug by enzymolysis of the pendallL linkages;
when the reverse sfim--l--s is applied, the enzyme becomes active and releases drug molecules by enzymolysis of the pendant linkages. A
hydrogel, with an enzyme ellLldl~ped within the gel is shown in Figure 11.
Figure 12 is a sch~m~fic illll~tr~ti~n of ssDNA hooks for "conjugating" the responsive polymers to the protein.
Figure 13 illu~LldL~s the synthesis of PNIPAAm with two carboxyl te~rmin~l groups using a two-component ilurt;lLtl system.
Figure 14 illustrates the synthesis of poly(NIPAAm/AAc) with a l~i.... ....~l hydroxyl group by chain Lldl~rel free radical copolymerization Figure 15 is a graph of the absorbance vs temperature of 0.2%
solution of poly (NIPAAm/AAc) in citric+phosphate buffers at pH 4.0 and 7.4. Ionic strengths of buffer solutions were adjusted by adding NaCI. Molar ratios of NIPAAm/AAc/2-ME/AIBN: 100/1/4/1, polymerization time: 20 min, polymerization Lel~lpe~dture 60'C.
Figure 16 is a schematic illustration of the use of a conjugate of a stimulus-interactive molecule and an interactive molecule such as an CA 02230~7 1998-02-26 enzyme, antibody, or receptor protein as an envh~ ,ellldl sensor. The sensor protein is protected and inactive until exposed to a stim~ c. The interactive molecule binds to a molecule such as an analyte, toxin, inhibitor or fouling agent. The sensor is regelleldled by removal of the S stiml-l--s (or, not shown, exposure of a second stiml-ll-c-interactive molecule to a second stiml-ll-s).
Detailed Des~ lion of the I~ liu ~
I. Stimulus Responsive-Interactive Molecular Conju~ates Stimulus-responsive components, most preferably polymers, and ligand-binding hll~;ldclive molecules are combined to produce environment~lly responsive interactive molecular conjugates. The stim--h-c-responsive colllpollt;lll is ~tt~rhPd to the interactive molecule at asite that affects the desired function of the int~r~ctive molecule, e.g., near the binding pocket of a ligand-receptor interaction. The functioning of the hlleldcLive molecule portion of the conjugate in recognition, complexation, reaction, sc:~aldlion, and delivery processes can then be controlled by a change in one or more external stiml~li, such as lelllp~ld~ul." pH, light, or electric field. The change causes the stim ,onsiv~;; component to undergo a collfc~lllldlional or physico-ch.omi~
change which could lead to structural transition (e.g., collapse or pl~ci~ildte, or the reversal thereof) at or near or distant (allostery) from the site of ~tt~chmtont, thereby modlll~ting the activity of the interactive molecule in the process.
Figure lA is a sch~m~ti~ of a conjugate 10 of a stim--ll-c-interactive molecule 16 bound to protein 14, where the stiml-ll~-c-interactive molecule 16 blocks the binding site 12 of the protein 14 when not exposed to the stim~ c and does not block the binding site 12 upon exposure to a stim--ll-c, or vice versa. When the binding site 12 is not blocked, a ligand 18 can bind to the protein 14.
In the preferred embo-liment the stimuli-responsive colll~onelll~
are synthetic or natural polymers that exhibit reversible conformational or CA 02230~7 1998-02-26 physico-chemical changes such as folding/unfolding transitions, reversible ~-~,ciyiL~ion behavior, or other col~ollllational chal1~es in response to changes in Lt;lll~c~dture, light, pH, ions or pl~s~ule.
Figure lB are l~l~se~ iv-e forms of tne stim~ interactive 5 molecule 16 of Figure lA, inrl~-ling linear homo- or co-polymers, grafts of comb or block copolymers, and star polymers.
Figure lC is a schPm~tir of an ~ iv-e embor~impnt~ where the stimlllu~-responsive molecule 16 is bound to the ligand 18, which in the presence of a stimlllllc is blocked from binding to the binding site 12 of 10 the protein 14, or vice versa.
Figure lD is a srhPtn~fi~ of yet another emborlimPnt which is e~ie.,li;.lly a combination of the embodimPntc of Figures lA and lC. The protein 14 includes a stimllluc-responsive polymer 20 which, upon exposure to a first stimllln~, blocks the binding site 12. The ligand 18 is 15 also conjugated to a stimnlllc-responsive polymer 16, which upon exposure to a second, dirL~Ic.lL stimlll~l~, blocks binding of the ligand 18 to the binding site 12. This provides a means for varying binding affinity as well as acting to prevent or allow binding.
1. Sl;..~ e~ iv~ ro~ .o~
A number of polymers respond with large physical changes to small changes in envil~",.~Pnt~l conditions, such as solution pH, ionic strength, solvent composition, L~ )el~Lture, light, and electric field.
These polymers are referred to as stimuli-responsive, envi-ul~ -lL~lly sensitive, "intelligent" or "smart" polymers. Hoffman, A.S., "Intelligent Polymers in Medicine and Biotechnology", Macromol. Svm~7., 98. 645 -664 (1995); also in: Artif. Or~ans, 19, 458-467 (1995).
Stimulus-responsive components useful to make the conjugates described herein can be any which are sensitive to a stimulus that cause significant conformational changes in the polymer coils, and which can be engineered to contain a group which is reactive with specific groups (e.g., ligands) on the interactive molecule of interest. Illustrative polymers CA 02230~7 1998-02-26 described herein are temperature-, pH-, ion- and/or light-sensitive polymers. Hoffman, A.S., "Intelligent Polymers in Medicine and Biotechnology", Artif. Or~ans. 19, 458-467 (1995); Chen, G.H. and A.S.
Hoffman, "A new l~ peldLule- and pH-responsive copolymer for possible S use in protein conjugation", Macromol. Chem. Phvs., 196, 1251-1259 (1995); Irie, M. and D. Kun~w~f~h~'~ln, "Ph~tolcs~o~ re Polymers.
Meçh~nnchtomi~try of Polyacrylamide Gels having Triphenylm~th~nP
Leuco Delivdli~es", Mao~cromol. Chem., Rapid Commun., 5, 829-832 (1985); and Irie, M., "Light-in~ ced Reversible Conformational Changes of Polymers in Solution and Gel Phase", ACS Polym. Plc~lhlL~., 27(2), 342-343 (1986); which are incorporated by reference herein.
Stimuli-responsive oligomers and polymers useful in the conjugates described herein can be synth~si7to~1 that range in molecular weight from about 1,000 to 30,000 Daltons, with a reactive group at one or both chain ends. In a ~rerell~d embo-lim~nt these syntheses are based on the chain L~dl~.rel-initi~t~(l free radical polymerization of vinyl-type monomers, as described herein, and by (1) Tanaka, T., "Gels", Sci. Amer., 244, 124-138 (1981); 2) Osada, Y. and S.B. Ross-Murphy, "Intelligent Gels", Sci.
Amer., 268, 82-87 (1993); (3) Hoffman, A.S., "Intelligent Polymers in Medicine and Biotechnology", Artif. Or~ans. 19, 458-467 (1995); also Macromol. Svmp., 98, 645-664 (1995); (4) Feijen, J., I. Feil, F.J. van der Gaag, Y.H. Bae and S.W. Kim, "Thermosensitive Polymers and Hydrogels Based on N-isopropylacrylamide", 11th European Conf. on Biomtls., 256-260 (1994); (5) Monji, N. and A.S. Hoffman, "A Novel Tmmlln~assay System and Bioseparation Process Based on Thermal Phase Separating Polymers", Appl. Biochem. and Biotech., 14, 107-120 ~ (1987); (6) Fujimura. M., T. Mori and T. Tosa, "Preparation and Properties of Soluble-Insoluble Immobilized Proteases", Biotech. Bioen~., 29, 747-752 (1987); (7) Nguyen, A.L. and J.H.T. Luong, "Synthesis and Applications of Water-Soluble Reactive Polymers for Purification and ImmobilizationofBiomolecules", Biotech. Bioen~., 34, 1186-1190 CA 02230~7 1998-02-26 (1989); (8) Taniguchi, M., M. Kobayani and M. Fujii, "Properties of a Reversible Soluble-Insoluble Cellulase and Its Application to Repeated Hydrolysis of Crystalline Cellulose", Biotech. Bioen~., 34, 1092-1097 (1989); (9) Monji, N., C-A. Cole, M. Tam, L. Goldstein, R.C.
5 No~villski and A.S. Hoffman, "Application of a Thermally-Reversible Polymer-Antibody Conjugate in a Novel Membrane-Based Tmmlmo~ y", Biochem. and Biophvs. Res. Comm., 172, 652-660 (1990); (10) Monji, N. C.A. Cole, and A. S. Hoffman, "Activated, N-S--bstih-te~ Acrylamide Polymers for Antibody Coupling: Application to a Novel Membrane-Based Tmmlmo~c~y", J. Biomtls. Sci. Polymer Ed.. 5, 407-420 (1994);
(11) Chen, J.P. and A.S. Hoffman, "Polymer-Protein Conjugates:
Affinity Precipitation of Human IgG by Poly(N-Isopropyl Acrylamide)-Protein A Conjugates", Biomtls., 11, 631-634 (1990); (12) Park, T. G.
and A. S. Hoffman, "Synthesis and Charac~c~alion of a Soluble, 15 T.,~ e,aLule-Sensitive Polymer-Conjugated EnzymeO, J. Biomtls. Sci.
Polymer Ed., 4,.493-504 (1993); (13) Chen, G.H., and A.S. Hoffman, "Plc~aldtion and Properties of Thermo-Reversible, Phase-Separating Enzyme-Oligo(NIPAAm) Conjugates", Bioconj. Chem. . 4, 509-514 (1993); (14) Ding, Z.L., G.H. Chen, and A.S. Hoffman, "Synthesis and 20 Purification of Thermally-Sensitive Oligomer-Enzyme Conjugates of Poly(NIPAAm)-Trypsin", Bioconj. Chem., 7. 121-125 (1995); (15) Chen, G.H. and A.S. Hoffman, "A New Tellly~ldLulc:- and pH-Responsive Copolymer for Possible Use in Protein Conjugation", Macromol. Chem. Phvs.. 196, 1251-1259 (1995); (16) Takei, Y.G., T.
25 Aoki, K. Sanui, N. Ogata, T. Okano, and Y.Sakurai, "Temperature-responsive Bioconjugates. 1. Synthesis of Temperature-Responsive Oligomers with Reactive End Groups and their Coupling to Biomolecules", Bioconj. Chem.. 4, 42-46 (1993); (17) Takei, Y.G., T.
Aoki, K. Sanui, N. Ogata, T. Okano and Y. Sakurai, "Temperature-30 responsive Bioconjugates. 2. Molecular Design for TelllpeldL~mor~ tP-1 Bioseparations", Bioconj. Chem., 4, 341-346 (1993); (18) CA 02230~7 1998-02-26 Takei, Y.G., M. ~t~l-k~t~, T. Aoki, K. Sanui, N. Ogata, A. Kik~-chi, Y. Sakurai and T. Okano, "Temperature-responsive Bioconjugates. 3.
Antibody-Poly(N-isvplul,ylacrylamide) Conjugates for Te~ alu~
Mo~ t~ leci~iL~tions and Affinity Biose~alaLions", Bioconj. Chem., 5, 577-582 (1994); (19) ~t~llk~t~, M., Y. Takei, T. Aoki, K. Sanui, N.
Ogata, Y. Sakurai and T. Okano, "Telll~eldLule Modulated Solubility-Activity Alterations for Poly(N-Isopropylacrylamide)-Lipase Conjugates", J. Biochem.~ 116, 682-686 (1994); (20) Chilkoti, A., G.H. Chen, P.S.
Stayton and A.S. Hoffman, "Site-Specific Conjugation of a Telll~.,ldLul~-Sensitive Polymer to a GenPti~lly-F.n~ ed Protein", Bioconj. Chem., 5, 504-507 (1994); and (21) Stayton, P.S., T. Shimoboji, C. Long, A.
Chilkoti, G. Chen, J.M. Harris and A.S. Hoffman, "Control of Protein-Ligand Recognition Using a Stimuli-Responsive Polymer", Nature, 378, 472474 (1995).
These types of monomers allow the design of copolymer compositions to respond to a specific stiml-ll-c and, in some embo(1imlont~, to two or more stim--li In addition, control of molecular weight (by control of reactant concentrations and reaction conditions), composition, structure (e.g., linear homopolymer, linear copolymer, block or graft copolymer, "comb" polymers and "star" polymers, all of which may be incorporated into gel ~.Llu~;Lulc:) and type and number of reactant end groups permit "tailoring" of the ~plu~liate polymer for conjugation to a specific site on the interactive molecule. A gen~ti~lly el~ ce~ed temperature-sensitive peptide sequence may be constructed at the Lel~ lal end of the protein near or within the binding site. Peptide sequences which are pH, light, temperature, or chemical sensitive have also been reported and may be used to control the molecular recognition step via conjugation to the receptor or ligand, or through genetic incorporation into protein receptors or enzymes.
a. Temperature-responsive Polymers CA 02230~7 1998-02-26 Illustrative embodiments of the many different types of ~ c;la~ul~-responsive polymers which may be conjugated to interactive molecules are polymers and copolymers of N-isol,lu~yl acrylamide (NIPAAm). PolyNIPAAm is a thP~ lly sensitive polymer that 5 precipitates out of water at 32~C, which is its lower critical solution LLul~:(LCST), or cloud point (~e~l~inc and Guillet, J. Macromol.
Sci.-Chem. A2: 1441-1455 (1968)). When polyNIPAAm is copolymerized with more hydrophilic comonomers such as acrylamide, the LCSTis raised. The opposite occurs when it is copolymeri7P-1 with 10 more hydrophobic comonomers, such as N-t-butyl acrylamide.
Copolymers of NIPAAm with more hydrophilic monomers, such as AAm, have a higher LCST, and a broader Lt;lll~el~ul~ range of prt~ iLalion, while copolymers with more hydrophobic monolll~,ls, such as N-t-butyl acrylamide, have a lower LCST and usually are more likely to retain ~e 15 sharp transition çh~rarteristic of PNIPAAm (Taylor and Cerankowski, J.
Polymer Sci. 13: 2551-2570 (1975); Priest et al., ACS Symposium Series 350: 255-264 (1987); and ~e~kin~ and Guillet, J. Macromol. Sci.-Chem.
~2: 1441-1455 (1968), the disclosures of which are incorporated herein).
Copolymers can be produced having higher or lower LCSTs and a 20 broader teln~ldLule range of plccipi~tion.
Stimuli-responsive polymers such as poly(NIPAAm) have been conjugated r~n~lomly to afflnity molecules, such as monoclonal antibodies, for example, as described in U.S. Patent No. 4,780,409; Monji and Hoffman, Appl. Biochem. Biotechnol. 14: 107-120 (1987). Activated 25 groups (e.g, for conjugating to proteins), were formed randomly along tne backbone of PNIPAAm and were conjugated randomly to Iysine amino groups on a monoclonal antibody and the conjugate was then applied in a temperature-in~ ced phase-separation immunoassay. Activated PNIPAAm has also been conjugated by Hoffman and coworkers to protein A, various 30 enzymes, biotin, phospholipids, RGD peptide sequences, and other interactive molecules. The random polymer-interactive molecular CA 02230~7 1998-02-26 conjugates have been used in a variety of applications based on the th~rm~lly-in~ retl phase sep~lalion step (Chen and Hoffman, Biu-llatelials 11: 631-634 (1990); Miura et al., Abstr. 17th Ann. Meet. Soc.
Biomaterials (1991); Wu et al., PolYmer 33: 46594662 (1992); Chen and S Hoffman, Bioconiu,eate Chem. 4: 509-514 (1993); Morris et al., J. Anal.
Biochem. 41: 991-997 (1993); Park and Hoffman, J. Biolllatelials Sci.
Pol~mer Ed. 4: 493-504 (1993); Chen and Hoffman, J. Bi- lllal~lidls Sci.
Polvmer Ed. 5: 371-382 (1994)). Others have also randomly conjugated ~ruL~ills to PNIPAAm (Nguyen and Luong, Biotech. Bioen~. 34: 1186-1190 (1989); Takei et al., Bioconj. Chem. 4: 42-46 (1993)) and to pH-sensitive polymers (Fujilllula et al., supra.)). Most of these polymer-protein conjugates involved r~n-lnm lysine amino groups of ~ ills bound to the polymer through random activated groups ~nddllL along the polymer backbone. More recently, a new metnod based on chain ll~ .Ç~
initiation poly,.,~ ion has been used which yields relatively low MW
polymers (called oligomers) usually with only one reactive end group (but the method may be adapted to synthesis of oligomers witn a reactive group at each end) (Otsu, T., et al. (1992) Eur. Polym. J.. 28, 1325-1329). (Chen and Hoffman, 1993, supra; Chen and Hoffman, 1994, 20 supra, and Takei et al., supra). The synthesis of an amino-t~....ill~tr~1 polymer proceeds by the radical polymerization of NIPAAm in the presence of AIBN as an h~ilialol and 1-aminoeth~n~-thiol-hydrochloride as a chain Ll~ .rel reagent. To synth~si7to a chain with -COOH or -OH
Ir~ groups, carboxyl- or hydroxyl-thiol chain Lldl~.r~,~ agents, 25 respectively, have been used instead of the amino-thiol. It should be noted that the synthesis of the end-reactive polymers is based on a chain transfer initiation and termination mechanism. This yields a relatively short polymer chain, having a molecular weight somewhere between 1000 and 25,000 to 30,000. The shortest chains, less than 10,000 in molecular 30 weight, are usually called "oligomers". Oligomers of different molecular weights can be syntht~si7ecl by simply ch~nging the ratio of monomer to CA 02230~7 1998-02-26 chain Llal~rel reagent, and controlling their concentration levels, along with that of the i,liLia~ol.
Oli~omers of Vinvl Monomers Oligomers of NIPAAm (or other vinyl monomers) having a S reactive group at one end are prepaled by the radical polyme.i~dLion of NIPAAm using AIBN as initiator, plus a chain Llal~re, agent with a thiol (-SH) group at one end and the desired "reactive" group (e.g., -OH, -COOH, -NH2) at the other end. Chen and Hoffman, Bioconju~ate Chem.
4: 509-514 (1993) and Chen and Hoffman, J. Biomaterials Sci. Polvmer Ed. 5: 371-382 (1994), each of which is incul~o,dl~d herein by l~fei~nce.
A~plupliate qn~ntitiPs of NIPAAm, AIBN and chain tldl~irel reagent in DMF are placed in a thick-walled polylllt;li~aLion tube and the mixtures are degassed by freezing and ev~c~l~ting and then Lhdwing (4 times).
After cooling for the last time, the tubes are ev~rn~t~d and sealed prior to 15 polymerization. The tubes are immersed in a water bath at 60~C for 4 h.
The resulting polymer is isolated by ~l~ci~iLdLion into diethyl ether and weighed to ~ e. ",i,-~ yield. The molecular weight of the polymer is ~rrnin~ either by titration (if the end group is amine or carboxyl) or by vapor phase osmometry (VPO). If a pH-selL~iLive oligomer or polymer 20 is desired, then acidic monomers such as methacrylic acid or acrylic acid, maleic acid or anhydride, AMPS, or the phosphate ester mt~llolllc,~
described above ("Phosmer") can be used, as can basic monomers, such as aminoethyl methacrylate (AEMA), or vinyl fo. ".,....irl~, which can be hydrolysed to polyvinyl amine after polymerization.
The molecular weight of vinyl-type copolymers can be controlled by varying the concentration of the key re~ct~ntc and the polymerization conditions. However, it is difficult to achieve molecular weights much above about 30 kD using synthesis of vinyl-based oligomers by chain LIOl~rel initiation. Further, since the amino-thiol chain transfer agent yields a broader molecular weight distribution than the hydroxyl or carboxyl thiols (which may be undesirable), the -COOH-tennin~tPd CA 02230~7 1998-02-26 polymer can be synthl-si7~cl and the -COOH end group converted to an amine group by activating with carbo~liimi~1e and coupling a ~ min~ tO
the active ester group.
Te~ eld~ulc: sensitive oligopeptides also may be incorporated into S the conjugates.
b. pH-sensitive Polymers Synthetic pH-sensitive polymers useful in m~king the conjugates described herein are typically based on pH-sensitive vinyl mo,lu~
such as acrylic acid (AAc), methacrylic acid (MAAc), maleic anhydride 10 (MAnh), maleic acid (MAc), AMPS (2-Acrylamido-2-Methyl-1-Plup~ lfonic Acid), N-vinyl form~mi~ie (NVA), N-vinyl ~cet~mi~
(NVA) (the last two may be hydrolysed to polyvinylamine after polylll~ tion), aminoethyl mtoth~-rylate (AEMA), phosphoryl ethyl acrylate (PEA) or m-qth~rrylate (PEMA). PH-sensitive polymers may also 15 be jy~lh~ k~ as polypeptides from amino acids (e.g., polylysine or poly~ ..,ic acid) or derived from naturally- occurring polymers such as ploL~ s (e.g., Iysozyme, albumin, casein, etc.), or polysaccharides (e.g., alginic acid, hyaluronic acid, carrageenan, chilos~ll, carboxymethyl cellulose, etc.) or nucleic acids, such as DNA. pH-responsive polymers 20 usually contain pendant pH-sensitive groups such as -OPO(OH)2, -COOH
or -NH2 groups. With pH-le~L~ol~iv-e polymers, small changes in pH can stim~ t~ phase-separation, similar to the effect of L~ Jcl~LLlle on solutions of PNIPAAm (Fujimura et al. Biotech. Bioen~. 29: 747-752 (1987)). By randomly copolylllcli~hlg a tht~rm~lly-sensitive NIPAAm 25 with a small amount (e.g. less than 10 mole percent) of a pH-sensitive comonomer such as AAc, a copolymer will display both temperature and ~ pH sel~iLiviLy. Its LCST will be almost unaffected, sometimes evenlowered a few degrees, at pHs where the comonomer is not ionized, but it will be dr~m~ti~ ally raised if the pH-sensitive groups are ionized. When 30 the pH-sensitive monomer is present in a higher content, the LCST
response of the temperature sensitive component may be "elimin~tecl"

CA 02230~7 1998-02-26 (e.g., no phase separation seen up to and above 100~C). On the other hand, graft and block copolymers of pH and k~ C~aLul~; sensitive monomers can be synthPsi7t-c~ which retain both pH and telll~JcldLul~
transitions independently. Chen, G.H., and A.S. Hoffman, Nature. 373, 49-52 (1995).
c. Light-sensitive Polymers Light-responsive polymers usually contain chromophoric groups pendant to or along the main chain of the polymer and, when exposed to an a~pl.~lidl~ wavelength of light, can be isomerized from the trans to 10 the cis form, which is dipolar and more hydrophilic and can cause reversible polymer co~ llational changes. Other light SC;l~iLiV~
compounds can also be converted by light stimn1~tic-n from a relatively non-polar hydrophobic, non-ionized state to a hydrophilic, ionic state. It is also possible to incorporate multiple ellvho.".,~nt~l sensiLiviLies in the 15 same polymer, such as Lelll~C,.dLul~ and light sensiLiviLy, by copolymerization.
In the case of pend~lL light-sensitive group polymers, the light-sensitive dye, such as aromatic azo compounds or stilbene delivdLiv~s, may be conjugated to a reactive monolll~i (an exception is a dye such as 20 chlorophyllin, which already has a vinyl group) and then homopolymerized or copolymerized with other conventional mon~
or copolymerized with telll~eldLule-sellsiLiv~ or pH-sensitive monomers using the chain L.dl~rel polymeli~dLion as described above. The light sensitive group may also be conjugated to one end of a different (e.g., 25 teln~ldLulc:-) responsive polymer. A number of protocols for such dye-conjugated monomer syntheses are known. Kungwatchakun and Irie, supra, and Mamada et al., supra.
Although both pendant and main chain light sensitive polymers may be synthesized and are useful compositions for the methods and 30 applications described herein, the preferred light-sensitive polymers and copolymers thereof are typically synthesized from vinyl monomers that CA 02230~7 1998-02-26 contain light-sensitive pendant groups. Copolymers of these types of monomers are y~yal~d with "normal" water-soluble comonomers such as acrylamide, and also with temperature- or pH-sensitive comonomers such as NIPAAm or AAc.
S Light-sensitive compounds may be dye molecules that isomerize or become ionized when they absorb certain wavelengths of light, COllv~l~llg them from hydrophobic to hydrophilic collro.lll~Lions, or they may be other dye molecules which give off heat when they absorb certain wavelengths of light. In the former case, the isomerization alone can cause chain expansion or collapse, while in the latter case the polymer will precipitate only if it is also Lt:lllyel~ -sensitive.
Light-responsive polymers usually contain chromophoric groups pendant to the main chain of the polymer. Typical chromophoric groups that have been used are the aromatic diazo dyes (Ciardelli, Biopolvmers 23: 1423-1437 (1984); Kun~w~ h~ n and Irie, Makromol. Chem Rapid Commun. 9: 243-246 (1988); Lohmann and Petrak, CRC Crit.
Rev. Therap. Dru~ Carrier Systems 5: 263 (1989); Mamada et al., Macromolecules 23: 1517 (1990), each of which is hlcc~lyOl~lL~d herein by reference). When this type of dye is exposed to 350-410 nm UV light, the trans form of the aromatic diazo dye, which is more hydrophobic, is isomerized to the cis form, which is dipolar and more hydrophilic, and this can cause polymer conformational changes, causing a turbid polymer solution to clear, depending on the degree of dye-conjugation to the backbone and the water solubility of the main unit of the backbone.
Exposure to about 750 nm visible light will reverse the phenomenon.
Such light-sensitive dyes may also be incorporated along the main chain - of the backbone, such that the conformational changes due to light-in~l~lce~l isomerization of the dye will cause polymer chain conformational changes. Conversion of the pendant dye to a hydrophilic or hydrophobic state can also cause individual claims to expand or collapse their conformations. When the polymer main chain contains light sensitive CA 02230~7 1998-02-26 groups (e.g. azo benzene dye) the light-stim~ tPd state may actually contract and become more hydrophilic upon light-in~ re~ isomerization.
d. Speci~c Ion-Sensilive Polymers Polysaccharides such as carrageenan that change their S conformation, for example, from a random to an ordered collro,lnation, as a function of exposure to specif1c ions such as K+ or Ca++, can also be used as the stiml~lns-responsive components. In another example, a solution of sodium ~lgin~tr may be gelled by exposure to Ca++. Other specific ion-sensitive polymers include polymers with pendant ion 10 çhrl~ting groups, such as hi~ti-1inr or EDTA, etc.
e. Dual- or Multi-sensitivi~ Polymers If a light-sensitive polymer is also thermally-sensitive, the UV- or visible light-~tim--l~tPd conversion of a chromophore conjugated along the backbone to a more hydrophobic or hydrophilic conformation can also 15 stim-ll~tP the dissolution or precipitation of the copolymer, depending on the polymer coln~osiLion and the temperature. If the dye absorbs the light and converts it to thermal energies rather than stim~ tin~ isol~ ion, then the lor~li7r~l heating can also stiml-l~fr a phase change in a lul~-st;l~ilive polymer such as PNIPAAm, when the system 20 lt;lllpCld~ult: is near the phase sepaldLion lc~ ldlUl~,. The ability to incolL,ol~le multiple sensilivilies, such as temperature and light sensilivily, along one backbone by vinyl monomer copolylllc.i~alion lends great versatility to the synthesis and p~u~el.ies of the r~pollsive polymer-~..gi..Fc~:d protein conjugates. For example, dyes can be used which bind 25 to protein recognition sites, and light-in~1llred isomerization can cause loosening or detachment of the dye from the binding pocket (Bieth et al., Proc. Natl. Acad. Sci. USA 64: 1103-1106 (1969)). This can be used for manipulating affinity processes by conjugating the dye to the free end of a temperature responsive polymer, such as ethylene oxide-propylene oxide 30 (EO-PO) random copolymers available from Carbide. These polymers, -(CH7CH70)x-(CH7-CHCH3-O)y-, have two reactive endgroups. The CA 02230~7 1998-02-26 phase sepaldLion point can be varied over a wide range, dependillg on the EO/PO ratio, and one end may be derivatized with the ligand dye and the other end with an -SH reactive group, such as vinyl sulfone (VS). In this way, the VS reactive end of the polymer may be conjugated to a specific 5 cysteine site located at a tli~t~nre away from the binding pocket, such that the dye conjugated to the other end of the polymer is still able to reach and affinity bind in the pocket when the polymer conformation is in the exp~n-le(l state. Then either a ~lllp.,ldlUl~ stim~ s or a combination of light and It~ pel~lule stimuli may operate to remove the dye from the 10 binding pocket, regellc;ldling it for further affinity binding (or for ell~ylll~lic activity, if it is an enzyme). This mtorll~ni~m is shown in Fig.
2c.
Random and Block CoPolvmers of EO/PO
Random copolymers of ethylene oxide (EO) and propylene oxide 15 (PO) also have LCSTs or CPs ("Polyethylene Oxide," F. E. Bailey and J.V. Koleske ~r~flemic Press, NY (1976)) and have two reactive end groups, so they may be conjugated by one end to the e,~gi..fel~:d protein and other re~t~nt~, such as the light sel~iliv~ ligand depicted in Figure 2C, may be conjugated to the other end. Telllpel~lulc~-sel~ilive block 20 copolyethers are also available (from BASF). Triblocks of PEO-PPO-PEO are called PluronicsTM or poloxarners, and tetrablocks are called TetronicsTM or polox~min~s. In the case of EO-PO random or block copolymers, a range of compositions, and molecular weights of these polymers having various reactive end groups can be obtained from 25 Shearwater Polymers, Inc. (Huntsville, AL). The compositions are selected on the basis of data available on their cloud points. (BASF
catalog, and "Polyethylene Oxide," F. E. Bailey and J.V. Koleske Academic Press, NY (1976)). A wider range of molecular weights of - these copolyethers may be ~paled than with the vinyl copolymers, since 30 their synthesis does not use a free radical chain transfer initiation process.
Derivatization of End Groups CA 02230~7 1998-02-26 The reactive end group(s) of the oligomer is (are) then derivatized with specific groups (e.g., vinyl sulfone or maleimide) which are selectively reactive with the site-specific group to be conjugated (e.g., the thiol functionality of cysteine). To introduce maleimide or vinyl sulfone S groups, an amine-tc~ oligomer is ~lercllcd. The amine end group of the polymers may be conjugated with maleimide to provide thiol-reactivity (Chilkote et al., 1993). A hydroxyl-termin~te~l polymer can be conjugated with vinyl sulfone by reaction with an excess of divinyl sulfone. The vinyl sulfone end group is typically more hydrolytically 10 stable than the maleimide in conjugation reactions wi~ protein thiol groups. Careful control of reactant stoichiometries and reaction conditions can yield birun.;Lional vinyl-type polymers such as polyNIPAAm or EO/PO random or block copolymers with dirrclcllL
functional groups on each end of the polymer.
2. IIlL~ Live lV~ol~c~ s The term"interactive molecule" as used herein inr~ es any molecule capable of a specific binding interaction with a target site, for example on a cell membrane, or on a molecule or atom. Thus, interactive molecules include both ligands and lcceL~Lul~.
a. Selection of Interactive Molecules The stim~llllc-les~u,~i~e colllpollcllLs can be conjugated to a variety of dirÇe.cllL interactive molecules, including peptides, proteins, poly- or oligo-saccharides, glycoproteins, lipids and lipoproteins, and nucleic acids, as well as ~yllLhcLic organic or inorganic molecules having a 25 defined bioactivity, such as an antibiotic or ~ntiinfl~mm~tl ry agent, and which bind to a target site, for example on a molecule such as a cell membrane receptor. In one plcfellcd embodiment the interactive molecule is a protein genPtic~lly engineered to insert a coupling site for the stimnlllc-responsive component at a desired site. Examples of protein 30 interactive molecules are ligand-binding proteins, including antibodies, lectins, hormones, and receptors, and enzymes. Other molecules which CA 02230~7 1998-02-26 bind specifically or non-specifically to a target molecule include poly- or oligosacharides on glyco~,oLtil~s which bind to receptors, for example, the carbohydrate on the ligand for the infl~mm~tory m~ tors P-selectin and E-selectin, and nucleic acid sequences which bind to complt;...~ .y S seqllenres, such as ribozymes, ~nti~en~e, external guide se~len~es for RNAase P, and a~,L~lc.~.
The interactive molecules are characterized by a binding site, which may be the active site of an antibody or enzyme, the binding region of a receptor, or other functionally equivalent site. These sites are 10 collectively referred to as the binding site of the interactive molecule, unless specifically stated otherwise. As described below, the stiml-llls-lc~l~ol~ive col~o~e~ls are used to modify and/or manipulate binding of a target molecule to the binding site of the i,~ d~;Li~e molecule.
The number of ~vlei"s whose interaction with specific binding 15 pa~ can be controlled via site-specific conjugation of a stimlll~
responsive component is quite large. These include, for example, antibodies (monoclonal, polyclonal, chimeric, single-chain or other recombinant forms), their protein/peptide antigens, protein/peptide hormones, streptavidin, avidin, protein A, protein G, growth factors and 20 their respective receptors, DNA-binding proteins, cell membrane l.,cept(JI~, endosomal membrane receptors, nuclear membrane receptors, neuron lt:C~Lol~ visual receptors, and muscle cell lec~L,l~.
Oligonucleotides which can be modified include DNA (genomic or cDNA), RNA, ~ el~e, ribozymes, and external guide sequences for 25 RNAase P, and can range in size from short oligonucleotide primers up to entire genes. Carbohydrates include tumor associated carbohydrates (e.g., ~ Le~, sialyl Le~, LeY, and others identified as tumor associated as described in U.S. Patent 4,971,905, incorporated herein by reference), carbohydrates associated with cell adhesion receptors (e.g. Phillips et al., 30 Science 250: 1130-1132 (1990)), and other specific carbohydrate binding CA 02230~7 1998-02-26 molecules and mim~ti-~s thereof which are specific for cell membrane receptors.
In one embo~lim~ont, where the stim~ ls-responsive coll~onellL is a polypeptide, it can be conjugated to the target interactive molecule, S especially a protein, at a genetically enginPered thiol ,-tt~rhm-ont site, or gen~tir~.lly fused into the DNA seql~n~e at an ~lO~liaLt: position relative to binding or active sites. (An~ew. Chem. Int. Ed. En~l. 32, 819-841 (1993)).
Among the ~loteills, streptavidin is particularly useful as a model 10 for other ligand-binding and substrate-binding systems described herein.
Streptavidin is an important component in many s~alaLions and diagnostic technologies which use the very strong association of the streptavidin-biotin affinity complex. (Wilchek and Bayer, Avidin-Biotin Technolo~v. New York, ~c~clemir Press, Inc. (1990); and Green, Meth.
15 Enzymol. 184: 51-67. Protein G, a protein that binds IgG antibodies (Achari et al., Biocl~P~ / 31: 10449-10457 (1992), and Ak~ .Ll.~lll and Bjorck, J. Biol. Chem. 261: 10240-10247 (1986)) is also useful as a model system. Representative immnnn~ffinity molecules include engin~ered single chain Fv antibody (Bird et al., Science 242: 423~26 20 (1988) and U.S. Patent No. 4,946,778 to Ladner et al., incorporated herein by l~re.~llce, Fab, Fab', and monoclonal or polyclonal antibodies.
Enzymes r~ sellL another inl~olL~llL model system, as their activity can be turned on or off or modlll~t~o~ by the controlled collapse of the stimlllll~-responsive component at the active site.
In addition to their well established uses in biotechnology, streptavidin, protein G, single-chain antibodies and enzymes are ideal model systems for several other important reasons. Genetic engineering systems for these ploteills have been established, allowing convenient site-directed mutagenesis and the expression of large qn~ntities of each protein 30 in hosts such as E. coli. High-resolution crystal structures are available that provide a molecular "road map" of the ligand binding sites (Achari et CA 02230~7 1998-02-26 WO 97/09068 PCT~US96/13874 al. supra; Hendrickson et al., Proc. Natl. Acad. Sci. USA 86: 2190-2194 (1989); Weber et al., Science 243: 85-88 (1992); Derrick and Wigley, Nature 359: 752-754 (1992); Mian, J. Mol. Biol. 217: 133-151 (1991)).
This structural info,ll~dlion provides a rational basis for the design of 5 affinity or activity switch site-directed .,.,.~ . Of course, ~l~teins which already have one, two or more ~;y~L~ e residues located at a site convenient for att~rhing a stim~ -lesyul~7i~e co"" one,lL are ready for ~tt~rllmPnt of the stimlllllc-lc~ol~i~/e component and need not have other cysteine residues en~illeelcd therein (unless another thiol group is desired 10 in a specific site or useless reaction of the wild type -SH group undesirably changes the protein bioactivity). Other sites on the ~luLt;ins can also be used, inrl~ ing amino acids substituted with non-natural amino acids.
Synthetic genes that direct the high-level e~res~ion of core 15 streptavidin and protein G in E. coli have been constructed. See, e.g., U.S. Patent 4,839,293, inco,~uldted herein by ~Ç~ ce. The genes incorporate biased codon usage for E. coli to m~ximi7~ expression, convenient restriction sites for c~sette mutagenesis, an i~ g methionine, and stop codons. The synthetic genes can inc~ o,ate 20 favored E. coli codon usage to m~ximi7P expression, and several restriction en_yme sites can be incol~oldL~d at unique sites within the gene to facilitate mutagenesis efforts. The gene sequence encoding the form of protein G for which the NMR solution structure has been reported (Gronenborn et al., Science 253: 657-661 (1991)) has also been 25 constructed. A single-chain Fv antibody gene has also been cloned and constructed from the parent antibody SS, which recognizes the CD44 - receptor antigen (S~n~m~ier et al., Blood 76: 630-635 (199O)). Single-chain antibodies consist of the variable heavy and variable light chains connPctPcl by a short peptide linker, and are constructed by using 30 polymerase chain reaction techniques to produce a single-chain Fv antibody(Bird et al., supra; Orlandi et al., Proc. Natl. Acad. Sci. USA

CA 02230~7 1998-02-26 86: 3833-3837 (1989); and Davis et al., Bio/Technol. 9: 165-169 (1991)), each of which is incorporated herein by reference.
b. Selection or crea~ion of Sites where Molecules are Bound The stimnl-lc-responsive component~s are covalently linked by their S end groups to the molecules at one or more selected sites, generally referred to herein as "coupling sites", such that, once the stim~ c-responsive colllpollellL is att~rhrcl to the molecule, the stimlllllc-respoILsive component coil remains in fhe soluble hydrated state. When the environmrnt~l signal or stimnlllc (or stimnli, depending on whether 10 different stimulus-respon~sive components have been ~tt~rhrt1) is triggered, the stimllhlc-responsive component may become more hydrophobic and the stimllllls-respon~sive component coil contracts and in some cases may "phase se~ate" (e.g., collapse) within or near the ~tt~chment site. In some cases, as with a light stimlllllc, the stimlllllc-responsive component 15 may both contract and become more hydrophilic due to isomerization in-lnced structural changes of a dye that is incorporated in the stimn responsive component.
Additionally, ion-sensitive stimlllllc-responsive components such as components capable of Ca+1 sen~sitive polymer conformational changes 20 may be used. Additionally, single stranded DNA, one end of which is ~tt~rhr(1 to a specific site on the interactive molecule, while the complementary sequence of base pairs is 5~tt~rh.od on one end of the stimlllns-responsive coll~ol1c;ll~ may be used, so that when the DNA pairs off, hooking the stim-llllc-responsive component to a specific site on the 25 protein, the rlict~nre the smart stimlllllc-responsive component ~tt~chmrnt is from the protein active site is controlled.
Typically the linkage site(s) will be (a) just out~side the binding site of the molecule, (b) at selected ~icf~nres away from the binding site, (c) just inside the binding sites, (d) deep inside the binding pockets, and/or 30 (e) at a selected site at some r~ict~nre from the binding site (f) at allosteric sites distant from the binding sites. When situated at a desired site near CA 02230~7 1998-02-26 the binding site of the molecule, sufficient hhld,allce, steric or ot_erwise, is provided by the contracted or collapsed stimnll-~ ol~ive component to adversely affect the ligand binding equilibrium while minim~lly affecting the affinity of the ligand for the molecule's binding pocket or S active site when the stiml~lnc-responsive colll~Jollent is in the e~cr~n~
state. Thus, upon stim~ tion, the ccllrc~llllational change or collapse of the polymer coil either inhibits, dilccLly or allosterically, the enL,~lce of the ligand to a protein binding pocket or an enzyme's active site and/or hl~lr~,~es with the ligand which is already bound within the site, thereby 10 c~-lcing its complete expulsion from the binding pocket or a reduction in affinity. The polymer can also be engin~ered to gradually collapse, which allows the col~ollllation of the polymer to be controlled, by gradual small, variations or changes in envholllllt;llL conditions, and thus the degree of reaction inhibition to be controlled over a range of interm~ te 15 ~mnitilos or reactivities. Recovery of the molecule's binding affinity or el.~ylnaLic activity can be effected by a return to the environm~nt~l conditions favoring the soluble, extended and hydrated random polymer coil. ~ tively, as shown in Figure 2b, in some cases the hydrated coil can block the binding pocket more erre~;Livt:ly than the collapsed coil.
20 Additionally, there may be an advantage to using a pendant reactive group on the polymer backbone to provide better blocking of the binding site.
To detellllille the optimal combination of polymer and ~tt~rhmPnt site(s) for a desired response, polymer composition and molecular weight can be varied, as can the type and m~gnitll(le of the stim--l--c and the 25 specific conjugation site or sites (e.g., two different or two similar stimnlll~-responsive components can be conjugated to two different sites).
If the light-sensitive group is along the main chains, it may be shortened in the hydrophilic state by the isomerization of the dye.
Sites for covalent ~tt~hmt-nt of the stimnl~ responsive component 30 on the interactive molecule may already exist or can be created by a variety of techniques depending on the nature of the molecule. For CA 02230~7 1998-02-26 example, if the molecule is a recognition protein that already contains a cysteine residue at a desired site, e.g., in or near an enzyme's active site, this native site can be used for ~tt~rhmPnt so long as conjugation of stiml-h-c~ ol~.ivt; col-.~o..elll to any other cy.leil~e residues that may be S present in the enzyme does not adversely affect the enzyme activity or the control exerted by the stiml-i~ responsive component at the active site.
When the molecule is a protein or nucleic acid, recombinant DNA
techniques can be used to provide a site if there is not one in the native molecule suitable for linking the stim--ll-~-responsive co.n~u..~--L.
10 Typically, a thiol side chain (e.g., one or more cysteine residues) is genrtir~ly engineered at a predetermined surface position at or near a ligand binding site of a protein, or at a distant site such as an allosteric site (depending on the desired action of the stim--ll-~). Techniques such as site-specific mutagenesis can be used and are described by, for example, Zoller and Smit'n, DNA 3:479-488 (1984), Sambrook et al., Molecular Clonin~: A Laboratorv Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989), and a useful polymerase chain reaction-mr~ tlo-l site-directed mutagenesis procedure is described by Stappert et al., Nucleic Acid. Res. 20: 624, (1992). Similar tprhniq~es can also be used to remove undesired sites that may occur in a native or wild type protein. Other reactive amino acids can also be en~in~ered and non-natural amino acids can also serve as unique ~tt~chment sites. When the affinity molecule is an oligonucleotide, thiolated oligonucleotides for stimulus-responsive component ~tt~rhmrnt can be inserted during synthesis, as described in Ede et al., Bioconj. Chem. 5: 373-376 (1994), incorporated herein by reference. With synthetic interactive molecules, unique chemic~l hooks such as thiols, amines, or hydroxyls can be synthetically incorporated at a~.v~liate positions near the recognition site.
The insertion sites are chosen so that the stim-ll~tion of the responsive stiml-ll-c-responsive component (or stimlllllc-responsive CA 02230~7 1998-02-26 component-ligand conjugate) at that position changes the ligand-binding affinity in the desired ma~ er. Two ~;y~.Leille residues can be engin~ered near the binding site so that the affinity will be altered by the precipitation ~ of two stimnll-~-responsive comyoll~llLs near the binding site, or one 5 cysteine residue is placed near the active site and one is placed within the interface b~lweel~ monomeric units of ~ ytavidin~ to provide a combined effect from the two acting together.
High-resolution X-ray crystallographic structures of the three yloleills are used to ~lrtf.,llil,.o ayyluyli~le positions for site-directed 10 mutagenesis. With modeling teçhniqlles, positions are located with ~yyro~liat~ solvent-~ccessihility for reaction with the stimnln~-responsive components, and positions deeper in the binding pocket are irlrntifiPd which require partial unfolding for conjugation. Sites are chosen at the subunit-subunit interfaces in streptavidin and the single-chain Fv antibody 15 to allosterically reduce the affinity by ch~nE~ing the protein structure by stimnl~ting a col~c,llllalional change in the polymer conjugated at a distant site. Numerous sites both around the binding sites of the three yl~Jlehls and at ayyloyliate allosteric sites away from the binding site can be used where the binding affinity will be reduced by stimnln~-responsive 20 Colllyollelll ~ ciyiL~liOn.
The site may also be chosen to be a certain ~ t~nre from the active site; then a ligand is conjugated at one end of the smart stimnll-~-responsive cclllyollellL and the other end is conjugated to the chosen distant site. An ayyl~yliate stiml-l-l~ can lower the ligand affinity in the 25 site and/or cause it to be pulled from the site; both actions may occur in some cases if the ligand-site affinity is affected by one stimulus and the stimulus-responsive component by a different stimulus, and the two stimuli are applied in sequence and/or siml~lt~n~-ously.
Once sites are chosen, c~csette or PCR site-directed mutagenesis 30 techniques are used to introduce cysteine residues at those positions. The engineered p~ hls are produced in E. coli, and then characterized, CA 02230~7 1998-02-26 including CD characlc.~Lion of secondary structure and binding affinity measurements, to confirm that the mutation itself has not adversely affected the protein ~LlucLulc, stability, and/or activity. The mutant plo~eills are then used for conjugation to the stimnlllc-responsive S cc,lll~oll~,.lL~ as described below.
To facilitate pl~3r~m~1lt of a sfimlllnc-responsive component ~tt~l~h.~.~llL site in or near the binding pocket or otner desired site, site-directed binding pocket ..,..~ can be produced to U~Lillli~c the thermodynamic and kinetic ~lupclLies specifically for use with stimnlllc-responsive colllpolltllL~. Such .. ~ display altered ligand ~fflniti~c and thus provide additional control over protein function for ù~ ;..g sfimlllll~-responsive component-molecular conjugates. Libraries of site-directed affinity .. ~ can be used. For example, several ligand-binding site mutations have been constructed in streptavidin which alter important biotin-binding interactions, as described in copending US
application Serial No. 08/387,055, incorporated herein by lcrclcnce. This provides a choice for the initial ligand-binding thPrmn~ly~ldlllic ~ruL~lLies, so that ch~ngçc in affinity triggered by the stimnllls-r~ol~ive coll-~o.~.lL
can be engintoered to fall in a useful and desired range.
Depending on the stim~llllc-responsive component's composition, molecular weight and location of the conjugation site(s) on the molecule, environmental stimnl~ls can be applied to affect: (a) the gradual or rapid and, if desired, reversible ~wiL;hillg of molecular binding interactions on and off, (b) the partitioning or sclJdldLion of the stimllhlc-responsive component-molecule conjugates (with or without their affinity targets) to selective surfaces, interfaces or second aqueous phases, and (c) a combination of (a) and (b), wherein the conjugates are first directed to a specific surface, interface, or phase, and then tne bound ligand is "switched off" (released) to the local microenvironment. In case (c) the two steps may be reversed in sequence. By applying small changes in envi,~ ,,lcllLal stimuli, such as temperature and/or pH and/or light~ to the CA 02230~7 1998-02-26 system, one can achieve environmental control over the stimllluc-responsive componen~-molecule microenYilo"l.l~llL, which ~elllliL~
molecular level control of the recognition and binding capability of dirr,L~,lL size and composition ligands with affinity ploleills or different 5 size and composition substrates with enzymes, selectively controlling the specific bioactivity of the molecule. The change in stiml-llls-responsive component collrolllldLion can also expose or block the active site of an enzyme, whose action is to release a bioch~mir~l or ch~nnir~l agent by enzymolysis of the agent's linkage to the smart stimnll-~-responsive 10 component.
The ~tt~rhmrnt site for the stimnlll~-responsive components can thus be directed to well-defined positions relative to the ligand binding site of each protein. Cysteine conjugation sites can be readily enginPered just outside the binding sites, at selected ~1i.ct~nres away from the binding 15 site, just inside the binding sites, deep inside the binding pockets, and/or at potential allosteric sites distant from the binding sites.
For example, the streptavidin Asn 49 residue lies in a solvent ~ccçc~ihle position on the border of the biotin binding site, and this residue has been mut~te~ to cysteine (N49C) using site directed 20 mutagenesis techniques. Large qu~ntities of this protein have been expressed and purified, and a vinyl sulfone-modified poly(NIPAArn) Lenll.~ldLul~-responsive stimulus-responsive component has been conjugated to this position. Streptavidin does not contain cysteine in its native sequence, making it convenient to introduce unique thiol side-25 chains. To design an exemplary site-directed mutant aimed at controlling its recognition processes as described herein, the general criteria center on choosing a site near the biotin binding site with signific~nt aqueous solution exposure at the atom where the thiol is substituted. One goal is to introduce a thiol with sufficient solvent exposure (to permit relative 30 ease of conjugation to the responsive stimulus-responsive component), and at a site where the collapse of the stimulus-responsive component should CA 02230~7 1998-02-26 WO 97/09068 PCT/L~S96/13874 sterically hl~lrel~ with ligand binding. The biotin binding site of streptavidin is covered by a loop that is extremely flexible and disordered in the ligand-free state. This loop becomes ordered and forms a "lid"
over the binding site when biotin is bound. This loop l( ~ sellL~ a target 5 for sfimlllllc-responsive component conjugation. The site-directed mutant places a ~;y~.L~illC at position 49 (Asn49Cys), which borders the lid.
Like streptavidin, protein G does not contain cysteine residues in the native structure. Protein G exists naturally as a multi-domain protein with high affinity for IgG antibodies and Fc derivatives. A small (55 10 amino acid) domain has been gen~tic~lly constructed, which retains native affinity for IgG (Ka> 107M-I) and which displays extremely high stability and a highly reversible folding/unfolding equilibrium (~lex~mlrr et al., Biochemistrv 31: 3597-3603 (1992)). Co-crystal analysis suggests that protein G recognizes IgG by forming an allLi~aldllel interaction beLwee 15 its second ,B-strand and the last ,~-strand of the antibody heavy chain C1 domain (Derrick and Wigley, Nature 359: 752-754 (1992)), while a solution NMR study suggests that the helix is involved centrally. Thus, ..... 1~.. 1~ have been made that introduced unique ~;y~L~ e residues near both sites. Three initial ~;y~.Lt:hle Ill~ i have been col~.Lll~c~d, with the thiol side-chain introduced at positions 11, 21, and 37. All three piuL~ S
have been expressed and purified in large qll~ntities for conjugation to thiol-specific stimlllllc-responsive culll~onellL~.
The ~li,llaly amino acid seque~res in the antibody family show a large degree of homology. The large library of high resolution, X-ray structures for cryst~lli7.od antibodies has conclusively demonstrated that these primary sequence homologies translate into a highly conserved three-dimensional fold (Padlan and Kabat, Meth. En~Ymol. 203: 3-21 (1991)), even within the variable domains where most of the variability is confined to six well defined hypervariable loops that constitute the antigen binding contacts. The remainder of the variable domain consists of a highly conserved ,B-sheet framework that is responsible for the f~mili~r , CA 02230~7 1998-02-26 antibody ,~-barrel fold. It is thus possible to generate a high resolution molecular model for single-chain antibodies of known sequence in the absence of X-ray crystal structure analysis (Martin et al., Meth. Enzvmol.
203: 121-153 (1991)), and several positions for introducing thiol side-S chains can be iclerltified.
c. Methods and Reagents for Conjugation Optimal solution conditions are used for site-specifically conjugating molecules to the genetically-engill~eled cysteines. The rllloTnir~lly reactive nucleophile is the thiolate anion. It is thus important to keep the side-chain reduced and to u~Lill-~e the conjugation pH. The pH and the stiml~ c-l~ e colllpone:llL's activated end group must also be chosen so that the colllpc~Lillg conjugation to the amino groups of lysine side-chains is avoided. The pH will also deLellllille the rate of hydrolysis of the thiol-specific electrophilic functionality on the ,ctiml-lllc-lc~ol~i~e component. Conjugation reactions to -SH groups are typically contluc~rd between pH 6 and 7.5, which is below the pH where Iysine amino groups are most reactive. The protein-engineered cysteine thiol groups often cross-link spontaneously in solution, so that one begins with ~li.clllfic1e-bonded dimers of protein G, etc. These ~liclllfi~1~s are reduced prior to conjugation using dithiothreitol, tris(2-carboxyethyl)phosphine (TCEP), or a similar reagent. TCEP does not react with the thiol-specific electrophiles, such as the vinyl sulfones to be used here, and can thus be used directly in the conjugation solution to ensure that the thiol is kept in the active oxidation state. Typical starting reaction conditions are 50 mM
phosphate buffer, pH 7.0, 100 - 300 ,uM protein, 1 mM TCEP (added at least twice), 50-fold molar excess stimulus-responsive component (to protein), room temperature, 2 hours. Common variations are temperature and time (e.g. overnight at 4~C) .
d. Separation and Purification of Conjugate The conjugation mixture is then passed over a SephadexTM G-50 gel filtration column. The stimulus-responsive component-protein CA 02230~7 1998-02-26 conjugate is sc~dldLed from the unreacted protein by thermal precipitation of the stim-llns-lc~po~ e COlllpOllcllL which brings the conjugates and any unreacted stimulus-responsive component out of solution. The conjugate and any unreacted stimnlll~-responsive component are then redissolved in S buffer and char~rteri7~ by SDS-PAGE electrophoresis. The conjugate is also characterized by HPLC andlysis on a GPC colurnn, where the conjugate runs at a different molecular weight than the free protein or stimlllllc-responsive component. MALDI-TOFS mass ~e-;Llullletry techniques can also be used to characterize the conjugate, which provides 10 high-resolution molecular weight analysis that is strong evidence of 1:1 stoichiometry. Control experiments are con~lurtP-I with wild-type protein, where there is no conjugation of the stimlllus-lc~oli~ive colll~ollcl~l, to confirm the specificity of the conjugation to the genPtir~lly e~ginPered cysteine of the mutant ~loLchls. Peptide mapping can also be conr1l-rte 15 to exactly chald-;lc,i~c which residue (i.e. the e~g;,.fe~cd cy~lcille) has been modified.
e. Optimization of Conjugation Reaction As the reactivity of e~ elcd thiols can vary widely depending on their position on the protein surface, there are ~ltern~tive reaction 20 conditions to the basic protocol given above to increase the efficiency of the conjugation reaction. For example, the reaction efficiency is often increased greatly by adding protein dcllaLuldliL~ at low col,cc,lLldLions.
These delldLuldn~ unfold the protein slightly and increase the accessibility of the thiol functional groups. As outlined above, the length of reaction, 25 temperature, and pH can also be varied to increase the efficiency of the conjugation reaction. In the above protocol, there is no separation of the unreacted stimnlll~-responsive component. In activity assays, a washing step can be used to remove excess stimnlllc-responsive component before qn~ntit~ting the binding affinity. However, it is possible that the excess 30 ctimnllls-responsive component would hltclrcl~ somewhat with the initial binding step~ and it may thus be desirable to remove the unreacted CA 02230~7 1998-02-26 stim~ lc-responsive component. This is done with streptavidin and protein G by running the conjugation mixture over an affinity column.
The streptavidin conjugates can be passed over a ~L~lldal.l iminobiotin ~ column so that the st;m~ s-responsive component-protein conjugate will 5 bind, while any free stiml-ll-c-responsive coll~ollel~L is washed through.
Similarly, protein G can be passed over a commercial IgG affinity column, with the conjugate binding to the column and the stimllll-c-responsive COlll~OllellL washed through. Ion-exchange chromatography can be used to separate conjugates with different stoichiometries if 10 stimllll-c-responsive components have been conjugated to lysine residues in addition to the genetically engineered cysteine.
The stimlllllc responsive component may be coupled to the molecule using conjugation methods available in the art, and described for example, in Taylor, Ed., "Protein Immobilization", Marcel Dekker, New 15 York, 1991; and Scouten, "Affinity Chiu---alography", J. Wiley % Sons, New York, 1981.
f. Linlcers (Spacers) between Stimulus-responsive Component and Molecule.
Although the foregoing description has focused on direct binding 20 of the stimlli-lc-responsive component to the molecule, linkers or spacer groups can also be used to connect the srimlll~ls-responsive component to the desired site on the molecule. Nucleic acids offer the additional advantage that they can be made complementary to a target and used for LalgeLi.~g as well as in combination with the stimllll-c-responsive 25 component to regulate access to the binding site. In a preferred embodiment, the stimulus-responsive components can be attached to a protein via an intervening oligonucleotide which is complementary in sequence to an oligonucleotide that has been conjugated to a specific site on the engineered protein (Figure 12). For example, an oligonucleotide 30 can be site-specifically conjugated to an engineered protein thiol, and its complementary sequence conjugated to an end-reactive stim--il~c-CA 02230~7 1998-02-26 lcs~ol~i~re component. (The DNA may also be conJugated to a reactive pendant group along the stim~ responsive component backbone). The base-pairing between the two complementary oligonucleotides to form duplex DNA will then result in the conjugation of the srimnll~s-responsive S co~ ,onenL to the protein near the engineered thiol ~tt~hm~nt site. Since the register of duplex formation can be exactly specified by the sequences of the two oligonucleotides, the conjugation ~ t~nre of the stim--lnc-responsive component to the thiol attachment site can be easily specified by the start site of duplex complementarity. This ~1ict~n~e can be used to 10 control the gating and switching activity of the stiml-ll-s-re~ol~ivc component at the protein binding site or enzyme active site.
g. Target Ligands The target ligands, as defined herein, refer to the molecule bound by the molecules defined above where the binding reaction can be 15 modified or otherwise manipulated through the interaction of the stim--l~
oll~ive component molecules bound to the molecules. These may be substrate, in the case where the molecule is an enzyme, ligand bound by a lcceplol, or a complementary nucleic acid. A specific site on the ligands, i.e., substrate, receptor ligand or comple~ ";1,y DNA, may also be 20 conjugated to a responsive stiml-ll~s-responsive component, with se~ ivily to the same or a different stim-~ll-c from that of the first stiml-ln~-responsive component bound to a specific site on the protein.
3. Immobili~tion of the Molecnl~s and/or T,i~n~lc on Solid Surfaces In some embodiments, the target interactive molecule may be immobilized to a solid support. This can be any form of porous or shaped solids, particulates, chromatography meclillm~ or other solid surfaces known to those skilled in the art. The molecules may be bound using commercially available reagents and standard techniques, usually 30 through the formation of covalent bonds or affinity interactions between the support and the molecules.

CA 02230~7 1998-02-26 As shown in both Figures 5 and 6, the interactive conjugates are ideal for use in sc~LIdldLions. As shown in Figure 5, one stimllll-c-responsive molecule can be used to control binding to a support to sepdldLe out of a solution or mixture a protein such as a biotinylated 5 protein that binds a target such as an analyte. The second binding site for the analyte can be further controlled through the use of a second stimllll-c-responsive molecule, which allows or blocks binding upon exposure to a stiml-l--c. This provides a means for ~lt?tecting a target molecule and ~uliryhlg the molecule, then regenel~ lg the starting materials so that 10 they can be used again. Figure 6 provides a variation of this method, where the target molecule is bound to an antibody linked to an intlif ~tor molecule, which if activated, serves as a signal to exposure the binding molecule, the streptavidin to a stim--ll-c which collapses a stim-~lnc-responsive molecule to allow binding and immobilization of the 15 steptavidin-antibody-target conjugate to a sub~LldL~.
To immobilize the stimnll~c-responsive collll~ull~llL/site specific protein conjugates to a stimnll-c-l~ ol~ive component ~u~ulL, covalent bonding of protein lysine groups to an activated polymer support surface can be used. Reactive groups (e.g., -OH, -COOH, -NH2) are needed on 20 the surface of the polymeric support, such as a microporous membrane, mi(;lopdlLicle, or a 96-well microtiter plate. The amine group is usually more reactive than the -OH or -COOH groups. There are several ways that amine groups can be formed on polymer surfaces, as depicted in Figure 9: (a) physical adsorption of polymers cont~ining amine groups 25 onto oxidized, ozonized or other negatively charged surfaces, where the polymer is bound mostly by ionic interactions, or onto hydrophobic surfaces where the polymer is bound mainly by hydrophobic interactions, (b) physico-chemical deposition of "polymers" cont~ining amine groups from amino-monomer (e.g., allyl amine, heptyl amine, etc.) gas 30 discharges; (c) chemical coupling of long chain alkyl amines onto hydrophobic substrates using an argon gas discharge; (d) ch~otni~

lt ~lktl (RNLE~ ~) CA 02230~7 1998-02-26 immobilization of amine polymer or their precursors by covalently-conjugating reactive polymer groups to reactive surface groups, or by physical adsorption of the polymer followed by treatment with ultraviolet radiation (uv), high energy radiation, or gas discharge; or (e) graft S polymerization of amino-monomers (e.g., ~minoethyl mPth~rrylate) using ozone, gas discharge, high energy radiation, or W to initiate the polymerization .
Vinyl fo,...~,..i-ir~ which is a polymerizable monomer whose dallL form~mi-le groups are readily hydrolysed to amine groups after polymerization, can be similarly surface graft polymerized. Acrylic or methacrylic acid, plus AAm or HEMA, can be graft copolymeLiGed to form surfaces with varying contents of carboxyl or hydlo~-yl functionalities. The carboxylated surfaces may also be used to physically bind, by ion-ion intrr~rtir~ns~ polycations such as polyethylene imine (PEI) or poly vinyl amine. In addition to these surface modifications, reactive mic-~ ~alLicles and microporous membranes can be purchased, e.g., from Bangs Labolatclies, Sigma, Polysciences, Millipore, Pall, Gelman, Sigma, Cole-Parmer, Alltech, etc. For example, hydrophilic PVDF microporous membranes onto which various polyamines (or their precursors) were first physically absorbed have been treated in a "flow-through" gas plasma, by moving the plasma through the membrane pores of a fixed membrane to covalently immobilize the polyamine (or its precursor). (In some cases, the membranes can be purchased with reactive surface groups).
Although described with reference to modification of surfaces with amine groups, the processes for formation of carboxyl and hydroxyl groups on surfaces are parallel processes.
Activation of the reactive surface groups, followed by immobilization of the stim~ c-responsive component/site-specific protein conjugate by covalent bonding of protein Iysine groups to the activated CA 02230~7 1998-02-26 polymer support surface, is accomplished using well established immobilization ch~ try methods.
II. Methods of Use of the Interactive Mo1ecular Conjugates The uses of the stim~ responsive component-directed affinity 5 and partitioning switches for the interactive molecules are as numerous and diverse as the biotechnological, mP~ l, Iaboratory, and industrial uses of the interactive molecules themselves. Thus, the stim~
responsive conl~ul~ interactive molecule conjugates are directly applicable to a wide variety of se~aldLions, sensors, diagnostics, 10 bioplucesses, biointeractions, and drug delivery systems, and can also be applied to the design and application of new technologies, such as control of enzyme rate plocesses, stimuli-in~lcecl phase-separation i~ a~s~ys~
regeneration/recycling of envhu~...,~"li.l sensors and biosensors, control of protein and cell interactions at foreign interfaces, and hlrulllldLion storage, 15 retrieval and sign~lling.
1. Affinity Switches An embodiment of a solution-based affinity system, an "affinity switch, " that is responsive to an external stimllluc which triggers reversible binding and release of the target ligands, which specifically 20 interacts with the interactive molecule of interest, is depicted in Figure la, where a unique thiol functionality 10 is located near the binding pocket 12 of a ligand-binding protein 14 and sulfhydryl-specific polymer chains 16 (illustrated as a "snake-like" ribbon structure) are conjugated to the protein 14 to provide externally-triggered steric inhibition of the 25 ligand binding equilibrium.
The release of the target ligand is controllable, and can occur in solution (typically accompanied by simultaneous precipitation of the stimulus-responsive component-affinity molecule conjugate after it has released the target molecule), or at a specific surface, phase, or interface, 30 where it can be immobilized on the surface at the interface, or ellLldp~ed within a hydrogel, in a capsule, hollow fiber, or a pore of a porous solid.

CA 02230~7 1998-02-26 Four dirrelcllL embo-lim~ontc of the affinity switch actions of the responsive polymer-interactive molecule conjugates are depicted in Figures 2a-d. Stim~ tion of the polymer may cause the ejection of bound ligand (Figure 2a) or steric blocking or unblocking of the binding pocket S (Figure 2b), or it may cause a ligand tethered to another site on the protein surface to be withdrawn from the binding pocket (Figure 2c), or the allosteric mo~lifle~tion of the affinity binding equilibrium within the binding pocket (Figure 2d). In order to enh~nre any of these actions of the conjugated polymer, it is also possible to conjugate more than one 10 polymer to different, specific sites on the protein surface, or to combine a site-specific conjugation of one polymer with non-specific conjugation of other polymer chains to the same protein. Figure 2c shows an embodiment where a stiml-ln~-sensitive polymer (e.g. Iight sensiliv~
ligand dye) is stimnl~tefl (e.g. with light) to cause a colll~llllaLional 15 change which reduces its affinity for the ligand bhldi~lg pocket, while the polymer chain conjugated to the interactive molecule is stimnl~te~l by a different stimnl-lc such as t~lllp~,ldLul~, causing it to contract or phase separate, the combination of these actions causing the lowered affinity ligand dye to be "pulled" from the pocket. Either stimlllllc can be applied 20 first, or the two may be applied ~imnlt~nrously. The combined action can result in the exposure of the open binding pocket for subsequent affinity binding by the ligand. Reversal of the stimllll-~ should permit reverse behavior.
The u~Lilllulll site within the pocket for each specific composition 25 and molecular weight of polymer for ejection of the ligand (e.g. biotin derivative in the case of streptavidin, for example) when the polymer is collapsed by raising the temperature, or exp~n-l.od by lowering the temperature, is determined initially by ntili7ing different molecular weight polymers such as PNIPAArn polymers of different molecular weight 30 (Figure 14). More (or less) hydrophilic copolymer compositions are then CA 02230S~7 1998-02-26 employed. These variables will infl~l.on~e the degree of conr~ ational change of the polymer chain with temperature.
In the case of the tethered ligand approach (Figure 2c), ~ birul~cLional responsive polymers of different molecular weights, can be 5 used to tl~ ....i...o the o~L~lllulll site for "uncorking" the ligand out of the binding site when the polymer is collapsed, for example, by raising the temperature. The "uncorking" may be tested with or without the light stim~ that affects the dye ligand binding affinity in the binding site (see also Figure 4). Similar strategies can be applied to protein G and 10 monoclonal antibody.
The affinity switch is particularly useful where the stiml-h-~-re~l,ol~i~e colll~ollellt is used to displace material which has bound to and fouled the affinity site as in the case of affinity-based environm~nt~l sensors, biosellsol~ or sepalaLions systems. Similar considerations apply 15 to the fouling of enzyme active sites in bioprocesses, as well as in the above application areas. Free protein binding sites, such as the antigen binding sites of antibodies or the active sites of enzymes, need to be regenerated for use in sensor, separation and enzyme technologies. For example, an antibody recognizing an environmental toxin might be 20 immmobilized on the surface of an optical sensor, where the binding of the target toxin leads to an optical signal that is transported to a detector.
For the sensor to be used again, the target toxin must be removed from the antibody binding site, without tl~m~ging the antibody or the optical sensor. In one embodiment, the stiml~l--c-responsive polymer-antibody 25 conjugate can be immobilized on the optical sensor, and after the initial binding and detection step, the target toxin can be removed without the need for harsh elution conditions by stim~ ting the polymer to switch the toxin out of the binding pocket. There is also a need to remove bound products from the active sites of immobilized enzymes, which inhibit 30 bioreactor catalysis through product inhibition. In a second embodiment, the stimulus-responsive polymer-enzyme conjugate can be immobilized in CA 02230~7 1998-02-26 the bioreactor, and when product inhibition becomes a problem, the enzyme active site can be regellel~Lt:d by sfimnl~ting the polymer to switch the product out of the active site. In a third embodiment, a pro-drug may be activated by enzyme-intluce~ release of an active drug, such 5 that reactivation of a fouled enzyme active site can lead to renewal of drug delivery. In some cases, the prodrug or a polymeric prodrug may be conjugated randomly or specifically to the enzyme, such that when the enzyme active site is rege,l~.dled by a stimn~ it causes a burst of drug release. The "cork-pulling" action depicted in Figure 2C may also be 10 used to re~t:nel~le enzyme activity upon stiml~l~ting the polymer and the ligand bound is the active site, as described above.
The binding ~ffiniti~os and/or the binding kinrtirs of the target ligands with the stimuli-responsive polymer-en~i.-P~l.,d protein conjugates are measured as a function of l~lll~.,.~lul~ change, pH change, or 15 hll~l~ily, time and wavelength of light (UV or visible) exposure. Binding assays include ELISA assays, radiolabel-based assays (e.g. equilibrium dialysis), and optical absorbance/ fluol~ ,cel.re-based assays. A well-established assay for ~let~rmining the off-rate of radiolabeled biotin is described in co-pending patent application USSN 08/387,055, and thus 20 increased off-rates with the stimulus-responsive polymer-streptavidin conjugate can be directly measured.
2. Partition-Switches The stimuli-responsive stimulus-responsive components can also provide a trigger for selectively precipiL~Iillg or partitioning a polymer-25 protein conjugate, in the latter case to a liquid-liquid interface, into a second aqueous phase, or onto selected polymer surfaces, as generally depicted in Figures 3a, b and c. The stim~ c-responsive component may be conjugated to specific sites away from the interactive molecule's ligand recognition site, so that the precipitation only causes phase separation, 30 referred to herein as "partition-switching", and not "affinity-switching".
After the externally-triggered precipitation of the individual polymer CA 02230~7 l998-02-26 WO 97/09068 PCT~US96/13874 chains occurs, the conjugates can aggregate together and ~le.~ te out of solution, as generally described for random conjugation of PNIPAAm to affinity ~ eills such as in the case of a PNIPPAm-~ antibody/antigen/second antibody conjugate/complex molecule 5 pr~ci~iLa~illg out of solution, by Monji and Hoffman, Appl. Biochem.Biotechnol. 14: 107-120 (1987) and also in the case of a PNIPPAm-protein A-IgG conjugate/complex molecule ~leci~ g out of solution, by Chen and Hoffman, Bio.l~alelials 11: 631-634 (1990)). Site-specific - conjugation of the polymer to the recognition protein as described herein 10 should lead to greater retention of the recognition capacity of the protein than random conjugation, e.g., to Iysine amino groups, on the protein.
In the ~,lesellce of a selected polymer surface, the ~lecipi~lillg polymer chains may selectively bind to ~ecirlc surfaces. Phase partitioning of the polymer-protein and polymer-molecular conjugates to a 15 second aqueous phase can also be directed by the ~,leci~i~ted polymer (Diamond and Hsu, Adv. Biochem. En~. Biotechnol. 47: 89-135 (1992);
Walter et al., Anal. Biochem. 197: 1-18 (1991); Hoffman, J. Biomat. Sci Polvmer Ed., 5 :555-568 (1994) .
These approaches offer at least two i ll~o.La~L advantages over 20 conventional methodologies: rapid reversibility of protein recognition processes and/or protein se~alalion processes using an enviro..,..k..l~l signal, and greatly reduced non-specific binding of interactive molecules to conventional support surfaces.
3. Combination Partition and Affinity Switches a. Using Two or More Stimuli-Responsive Stimulus-responsive components with Di~ferent Functions The affinity trigger and partition trigger capabilities can also be combined with the same interactive molecule such that two different ~tim~ c-responsive components are conjugated at two different locations.
Partitioning is triggered by a different external signal than that which triggers the ligand blocking/unblocking or binding/release actions. With CA 02230~7 1998-02-26 dual triggering capabilities, for example, as shown in Figure 4, a interactive molecule-stimuh~s-responsive cumL)olle-lL conjugate, with its target ligand bound, can first be phase-separated by triggering the sfim~ -s-responsive component conjugated away from the binding site, 5 followed by the use of a second signal which triggers the affinity switch and releases the ligand, in a desired phase or at a desired surface. This can be accomplished by ~tt~rhing one class of stimulus-responsive component near the ligand binding pocket, for example, a light-sensitive polymer, and a ~e~dlal~ polymer chain at the partition triggering site, for 10 example, a temperature sel~iLiv~ polymer. AlL~ laLi~ely, two stimlllll~_ responsive components within the same class, but with distinctly different stimuli-responsive conformational fh~,~g~s (e.g., having two different phase sepaldtion tempeldLul~,s), can be used.
b. Using Mixed-function Conjugates The ability to genc;ldl~: streptavidin te~ from non-identical monomer subunits permits unique uses of the polymer-protein conjugates which require mixed functional plopelLies. For example, two of the subunits can be individually en~hlcel~d with cysteine attachment sites near the binding site. These sites can then be conjugated with, e.g., 20 Lelll~eldLIlle-responsive polymers, thereby providing a temperature-controlled affinity switch. The rrm~ining two ~ubuniL~ can be individually engin~ered to contain engil-reled ~;y~Leil¢ residues located away from the binding site, for the conjugation of different stim-~ll-c-responsive components, e.g., pH-sensitive polymers directing selective 25 pH-responsiveness, such as precipitation, or providing a pH-sensitive partitioning switch. The mixed-function polymer-streptavidin conjugates thus combine a temperature-sensitive ligand affinity binding switch with a pH-sensitive selective partitioning trigger. Similar mixed dual response conjugates can be made from two different telllpcld~ulc:-sensitive polymers 30 that have different cloud point temperatures (see Figures 5 and 6). The CA 02230~7 1998-02-26 polymers themselves may also be composed of both temperature and pH
components, or other combinations of different sensitivity components.
c. Rate- or A~inity- Controlling Switches - As ~liccnccpd above, the size and collrcllll~lion of the stimllhl~c-5 responsive component can be used not only to block binding, i.e., turn binding "on" or "off", but also to regulate the rate and extent (or affinity) of binding as well as to selectively permit only ligands below a certain size to have access to the binding site. Once the size of the binding or active site and the affinity ligand or enzyme has been dete-...;..~d, one can 10 select the molecular weight, composition and structure of the polymer, which will define the stimlllllc-intlnced conformational changes of the stimlllllc-responsive component to dete~ ine the extent to which the site is blocked. It is routine to optimize the extent of blocking which is desired, for example, by conjugating a series of stim~ lc-responsive C~ of dirrel~lll molecular weights or compositions to the interactive molecule and measuring binding before and after exposure to a stimlllllc which alters the conformation of the stim~llllc-responsive component.
The inll~lerlre of polymer composition, molecular weight and structure, and the type and m~gnitll-lP of the srimlllllc applied to the polymer can be determined for each target ligand or cell to the immobilized stimlllnc-responsive component/site-specific protein conjugates. The srimlllllc-responsive component properties and the site-specific cysteine location(s) for the most controllable and reproducible "on-off" responses of each of the three affinity recognition proteins can thereby be optimized for each ligand.
4. Specific Applications Due to the ability to control the affinity interaction between the interactive molecule and target ligand, many uses of the conjugates described herein are found in separations. diagnostics, sensors such as environmental sensors and biosensors, drug delivery, bioreactors and immobilized enzyme technologies, biocompatibility, etc. For example, in CA 02230~7 l998-02-26 the case of an enzyme, stim~ responsive, "on-off" or mc-clnl~te~l control of enzyme activity can be achieved, (e.g. control of turnover rate and substrate size-specificity), a feature that has important uses in bioreactors, sensors such as biosensors and ellvilulllllental sensors, se~dldtions and 5 drug delivery.
a. Separations Appl~cations In s~pd,aLions applications, the sfim~ -responsive culll~ull~llL/site specific interactive molecule conjllg~t~s are useful in, e.g., low pl~ Ul~
chromatography, high pelrc~ ance liquid chlulllatography, affinity 10 ~ iLdlion se~.alions, membrane se~a~dLions, immunoadsorption separations, and two phase aqueous s~pa-d~ion systems. Site-specific binding molecules such as ~lle~ vidin, protein G, and monoclonal antibodies, exemplified herein, are the most widely-used affinity ~rolei in current affinity sep~ inns systems. The widespread uses of 15 streptavidin, antibodies, and protein G are ~ cllc~e~l in Wilchek, 1990, su~ra; Harboe et al., J. Clin. Microbiol. 28: 913-921 (1990); Katz and Siewierski, J. Chromatogr. 624:403-409 (1992); Meyer et al., Exp.
~em~tol. 19: 710-713 (1991); p~g~n~lli et al., Int. J. Cancer 45: 1184-1189 (1990); and Yarmush et al. Biotechnol. Pro~. 8: 168-178 (1992).
20 Rec~llse streptavidin and a biotinylated antibody, protein G, and IgG are often used together, the conjugation of a stimlllllc-responsive colll~olle to one or both of them provides the OppOl~u~ y to seqll~nti~lly (and temporally) regulate the affinity of each CCIlllpOll~,~lL. Each protein can be modified with a stimllllls-responsive collll)ol~.lL to respond to a different 25 or unique stimulus, allowing specif1c interfaces and molecular interactions to be switched on or off by the choice of stim~ s.
A representative dual affinity trigger separations application is illustrated schematically in Figure 5. As shown in Figure 5, one stimulus-responsive molecule can be used to control binding to a support 30 to separate out of a solution or mixture a protein such as a biotinylated protein that binds a target such as an analyte. The second binding site for CA 02230~7 1998-02-26 the analyte can be further controlled through the use of a second stim~ -c-responsive molecule, which allows or blocks binding upon exposure to a stim-lh-c. This provides a means for ~letecting a target molecule and - purifying the molecule, then regcllclatillg the starting materials so that they can be used again.
For example, the streptavidin-biotinylated antibody hlLelaclion can be controlled with temperature, while the antibody-target antigen interaction can controlled by pH. Two different te,l,pe,dlu,c-responsive polymers can also be used, where, for example, the external ~ CldLUlC
is raised to affect the release of the biotinylated antibody-target ligand from streptavidin first, and then the target molecule is sepd,dtcd from the antibody by raising the Le~ dLu~c: a few more degrees. While a solid ~up~!oll for the reaction can be used, e.g., using a conventional chromatographic resin, an HPLC support, membrane, bioreactor surface, etc., the affinity switches can also be applied to ~lcci~Jildlion or two phase, aqueous sc~dlaLion strategies. The physical ~,ro~ ies of the partially or totally collapsed polymer, which is usually hydrophobic, differ .si~ir;c~ ly from the extended coil, which is usually hydrated and hydrophilic, providing the driving force for reversible partitioning bcLweell two aqueous phases.
In another example, an o~li",i;~ed stimllll-~-responsive component-engineered protein conjugate system is ~ signf cl for selective sc~dldlion of Iymphocytes or other cells carrying biotinylated monoclonal antibodies bound to cell rccepto~ Lthls or carbohydrates.
Stimulus-responsive component/site-specific protein (streptavidin) conjugates are immobilized onto Bio-Rad acrylamide-acrylic acid gel beads which are currently used for selective lymphocyte cell separation protocols. The beads have carboxyl functionalities, and avidin is immobilized to the beads using conventional carbot1iimi-1e activation protocols. The cell selections are carried out with bone marrow or peripheral blood, or model system ~c~alalions using a biotinylated CD34 CA 02230~7 1998-02-26 antibody, which binds to stem cell CD34 membrane receptors which are present in the cells that are to be positively select.ocl The cells which are selPctt~d by binding to the column are removed by gentle squeP7ing of the flexible column followed by eluting the se~a,clL~d cells from the column.
5 Since the cells break off the column and leave behind the biotinylated CD34 antibody, which is still bound to the immobilized streptavidin conjugate, the stim~ spollsive col"l,one"l/ streptavidin conjugate is ~timlll~ttofi to eject the biotinylated antibody to be able to reuse the column. The ability to reuse the column is useful for SclJdld~io 10 applications other than bone marrow separations.
Separation of Antibodies usin~ an Immobilized Stimulus-Responsive Component-Protein G Conju~ate.
In still another example, the optimized stimnlllc-responsive cc lllpone,.t/site-specific protein conjugate system is used for sepal~tion of 15 antibodies with an immobilized stimnlll~-responsive component-protein G
conjugate. A biotinylated stimllhl~-responsive colll~olltllL/ protein G
derivative (biotinylated via amino groups from Iysine side-chains) is immobilized in streptavidin-coated microtiter wells, using streptavidin-conjugated Sepharose as a stationary support. The stimllln~ ,s~ol~ivt;
20 component-protein G conjugate can be covalently immobilized on commercially available Sepharose beads through the amino groups of Iysine side-chains. This system is then applied to separation of IgG
antibodies. A solution cont~ining IgG (e.g., whole blood, blood plasma, blood serum or a bio~rocess product stream) is reacted with the Sepharose 25 affinity beads and IgG binds to the Protein G. The antibodies are first bound under environmental conditions where the stimnllls-responsive component is in a physical state where binding is allowed. The beads are rinsed and the IgG molecules are released with the ap~,u~-iat~
temperature, pH, light or other stimulus switch. Conditions are 30 deterrnined for sequential binding and release using a pure antibody preparation, and l~ Lul~S of antibodies and other proteins, including CA 02230~7 1998-02-26 whole blood, blood plasma, and whole cell extracts cont~ining antibodies.
The initial runs are con~lnctto~l as a function of ionic strength to ...i..i.~.i,ts non-specific hlL~ldcLions. In the case of separation of IgGs from whole ~ blood or plasma, the IgGs may first be concellLlated from whole blood by 5 cryoprecipitation, then rewarmed to redissolve, and affinity-purified on the Protein G column as described; this will avoid the need to handle large volumes of blood or blood plasma in the Protein G column.
Selective Separation of Specific Anti~en Carryin~ Cells.
The immobilized stim-llns-responsive polymer-scFv antibody site-10 specific conjugate system is also used for selective sel,aldlion of specific antigen-callyhlg cells, such as CD44 cells. The same immobilization approach as that described above is used to cross-link the stimllllls-responsive polymer-scFv antibody conjugate to Bio-Rad acrylamide-acrylic acid gel beads. As the S5 scFv antibody can be biotinylated 15 through lysine groups without altering the binding affinity, avidin-coated beads can be used as well to immobilize the scFv conjugate. The affinity switch can, for example, then be used to isolate human peripheral blood mononuclear cells (PBMC) which express the CD44 antigen, starting with pure PBMC cells and procee(ling to more complex llli~lur~s, as well as 20 cells that express lower qn~ntiti~s of CD44 which can be discl;~ r-against.
General Advanta~es for Separations There are many ~i~"irir~ advantages of such stim~ -c-responsive component/site specific protein conjugates in separations, such as: 1) 25 gradual or rapid and qn~ntit~tive elution of the bound target ligand, provided by the stimulus-responsive component which is conjugated near the protein active-site; 2) external stimuli used to trigger stimnll-s-responsive component precipitation and conjugate phase partitioning are mild compared to ~;u~ lLly required elution conditions, and are thus more 30 likely to preserve the integrity of target molecules; 3) gradual or rapid reversibility between on and off binding states. which provides more CA 02230~7 1998-02-26 versatile and cost-effective separation systems; 4) the opposing factors of selectivity and separation efficiency can be optimized by moving the stimull~c-lc~pul~ive component conjugation site closer to or further away from the binding site or active site of the protein or enzyme, as desired 5 and also the composition of the polymer may be modified to control its collfollllaLion as a function of the level of the stimll1uc, such that only certain size ligands may bind during exposure to a complex llli~Lulc, e.g., by raising the temperature to partially collapse the polymer chain and block the binding of large ligands, but still l~ i..g below the 10 Lclllp~,,aLulc where the polymer is completely collapsed, followed by raising the Lclll~,ldture higher to eject and recover or discard the small bound ligand; 5) the stimlll~lc-lc~pol~ive culll~oncllt can act to stabilize the affinity protein in solution or on a surface, thereby providing a longer ~cldLhlg time and greater economic advantage for the sc~al~Lion process;
15 6) in the case of the stimlllllc-responsive colll~ollclll-streptavidin conjugate witb biotin as the target ligand, the biotin may be conjugated to a wide variety of interactive molecules, such as antibodies, drug molecules, enzymes, peptide lig~nri.c, and cell receptors, all of which permit a myriad of potential applications for the stimllllls-responsive component/site 20 specific protein conjugate system, 7) the stimlllnc-responsive component composition and molecular weight can be adjusted and m~tchPA to each conjugation site to o~LillP7c the desired lc..~onse (e.g. type, m~gnihl(le~
rate, for example, where a collapsing polymer is used to selectively separate small and large ligands with the same affinity ligand constructs).
25 Other advantages include the ability to block ligand access to the binding site until the stimulus is reveresed, expanding and hydrating the polymer coil.
b. Diagnostic Applications In vitro diagnostic methods can be ~PcignPc~ which employ 30 stimulus-responsive component/engineered protein conjugates. For example, in one embodiment, depicted in Figure 6, illustrating an CA 02230~7 1998-02-26 immnnoa.cs~y format using the stimuli-responsive polymer-inL~;~a~;liv~
molecule conjugate compositions, the protein is streptavidin and is used in conjunction with a biotinylated monoclonal antibody. An exemplary assay begins with a homogeneous, solution-phase i.~ b~ion of the biotinylated 5 monoclonal antibody with the analyte solution, which contains the antigen plus an added, labeled monoclonal antibody to a different epitope on the antigen, forming the i.. -.. P complex sandwich. This is followed by addition of the stimnll~s-responsive polymer/streptavidin conjugate, which will bind the biotin conjugate, after which the polymer is stimnl~t~ to 10 affect a physical ~~a~dLion to isolate the analyte and the signal antibody complexed to it. This homogeneous inr~lb~til~n/phase sepd dlion ter.hniq~-~offers signifir~nt advantages over conventional solid-phase ELISA
technology, which include: 1) ability to complex large analytes in a homogeneous inrllb,.ti~n step; 2) greatly reduced background signal 15 caused by non-specific binding of the labeled monoclonal antibody on solid surfaces binding with solution phase binding steps; 3) avoidance of the partial loss of Ab recognition sites arising from its physical adsorption in an unfavorable orientation on solid surfaces, as in ELISA; and, 4) reduced processing requirements, including signifir~ntly reduced washing 20 requirements, along with speedier acquisition of results. These diagnostic protocols can be used with a monoclonal antibody, and therefore, any specific antigen targeL. They also provide rapid and efficient ~ illlUlll monoclonal antibody/ antigen binding, because the recognition step occurs in solution. The processing of test results also has .signifir~nt advantages 25 over traditional methods, with controlled rate or fast response to external signals such as light or te,l,pe,dLule, and ability to test multiple samples using colorimetric-based assays (e.g., using microtiter well surfaces to collect, by triggering the phase separation onto the surface, the polymer-streptavidin/biotin-monoclonal antibody/antigen/secondary labeled MAb 30 conjugate/complexes.

CA 02230~7 1998-02-26 In another application of this technology, when the polymer is in the collapsed state, the sensor action is turned off since the analyte ligand cannot bind to the recognition protein. This "off" state also serves to protect the protein's active site from fouling by various agents in the 5 ellvhulllllent. In this case, it may be desirable to be able to turn "on" an ellvilulllllental sensor only at specific times, in order to sample the collcenLldtion of a particular analyte in the ellvhu~ ent at those times, while ret~ining the sensor protein in a protected state the rest of the time.
In addition, there are disposable sensor packets that operate by flow of a 10 test solution col~;i,.g multiple analytes through various sensing channels col,l;1i"i"g different sensing elementc. In this case, it may be desirable to turn "on" the sensor protein only when the test solution has reached and becolllc distributed within the recognition protein channel in the most effirieIlt lll~ er. In both of these examples, after the sensing is completed, the action of the recognition protein is r~ene.~ted by reversing the stiml-l--c (e.g., heating) to remove the analyte from the active site, and to keep it in the "off" state thereafter until needed once again.
c. Drug Delivery Applications The stimnll~c-responsive component-protein conjugates described herein provide a signifir~nt means for combining drug L~lgetillg capabilities or in vivo diagnostic methods with triggered delivery.
Streptavidin has been used in targeted drug delivery systems by first conjugating it to a Lal~Lillg moiety such as a carbohydrate ligand for a cell membrane receptor or an antibody and injecting it to deliver it to a specific cell, and then injecting and binding to it biotinylated im~ging or therapeutic agents such as radio-isotopes or anti-cancer drugs. Bickel, 1993; Pardridge, 1992; Sheldon, 1992; and Paganelli et al., Int. J. Cancer 45: 1184-1189 (1990), each of which is incorporated by reference herein.
AlL~lllaLively, two and three step pretargeting methods can provide benefits of higher specificity and faster clearance of more toxic CA 02230~7 1998-02-26 th~,ld~ulics or im~;ng agents, where the biotinylated carbohydrate or antibody is first ~lminict~red, followed by injection of a streptavidin-biotinylated tht:ld~cuLic complex (two-step), or followed by ~ L~vidin ~ and after that subsequently with the biotinylated therapeutic (three-step) 5 (p~g~n~olli et al., supra.).
SL~ ,Ldvidin's usefulness arises from its multiple binding sites (as well as its high affinity for biotin), so that one binding site can be used to target the protein and other sites can be used to complex biotinylated therapeutics or im~ging agents. In the case of stim~ -c-le~,ol~.ivt:
10 component-streptavidin conjugates, a biotinylated drug can be complexed in a streptavidin binding site which is complexed to the streptavidin-monoclonal antibody (SA-MAb) conjugate, and its release can be triggered later with a stim--hlc to collapse the polymer and eject the biotinylated drug.
A light-triggered affinity switch is particularly useful in drug delivery applications, where release of tht:la~uLiCS after Ldlgeling is stimlll~t~l by collapsing the polymer, as depicted in Figure 7. This method is especially useful for topical delivery, ophth~lmic drug delivery, and internal delivery using catheters h~.Llulllented with a laser light source 20 and optical fibers, to stim~ te site-specific release. The collapse of the polymer chain can also be accomplished while its conjugate is complexed to a cell membrane receptor, which could stimlll~t~ receptor-m~ tt~-l endocytosis. In such a case, the delivery of the drug can be triggered directly into the cell, within an endosome, for example, by triggering a 25 polymer-antibody-drug conjugate (polymer-immnnnconjugate). In this embodiment the antibody is engineered to provide a reactive -SH site for the polymer away from the binding site of the monoclonal antibody. The drug can be randomly conjugated to the monoclonal antibody or it can be conjugated to the polymer. The drug will be released inside of the 30 endosome, for example, where the linkage of the polymer to drug is labile CA 02230~7 1998-02-26 to a pH of approximately 4 or 5, the pH of the endosome, as shown in Figure 8. Figure 8 shows sch~m~tir~lly the delivery of a srim~
responsive polymer-interactive molecular conjugate to a cell where drug release is by pH dependent cleavage of a linker to the drug.
S Enzyme-m~ t~d drug delivery occurs by enzymolysis of prodrugs (i.e., inactive drug precursors, such as esterified acidic drugs). This approach is being utilized by ph~ ti~l companies for enhal,chlg drug penetration across cell barriers, such as in mucosal delivery systems.
If a prodrug is synth~ 7~ by conjugating the drug to an enzyme inhibitor 10 via an enzymolyzable bond, then complexation of that prodrug-inhibitor conjugate to the enzyme will block its enzymolysis. If a stimuli-.o~ e polymer is specifically conjugated near the active site of the enzyme, then triggelh~g the polymer to eject the inhibitor will trigger the enzymolysis of the prodrug and release of active drug. The prodrug may 15 also be ~ylllh~5i~ by conjugating it via enzymolysable bonds as pendant groups along a polymer backbone, with the enzyme inhibitor also being conjugated s~ ly to the polymer. Then when the prodrug polymer-inhibitor is ejected from the active site by the stimlll~fion of the polymer conjugated to the enzyme nearby its active site, many drug molecules will 20 be released by enzymolysis. The enzyme or enzyme-prodrug complex may also be targeted to specific sites, e.g., using biotin-streptavidin complexation as described above.
Figures 9a-c are sch.om~ti~s of three general methods for physical or chemical immobilization of a stimulus-responsive polymer-interactive 25 molecular conjugate to a surface. In the first of the three general methods, (a) the interactive molecule may first be immobilized by non-specific adsorption (e.g., ionic, hydrophobic, etc.) or by affinity binding to surface ligand groups, or by ch~mic~lly-coupling it to reactive surface groups, followed later by ch~mi~l conjugation of the responsive polymer 30 to the surface-immobilized interactive molecule. or (b) the responsive polymer is first chemically-conjugated to the interactive molecule and then -CA 02230~7 1998-02-26 the conjugate is immobilized onto the surface by non-specific adsorption, or by affinity binding to surface ligand groups, or by chemically-coupling it to reactive surface groups, or (c) by first physically-adsorbing the - responsive polymer onto the surface, or chrmir~lly-coupling the S responsive polymer to reactive surface groups, followed by chlomir~l conjugation of the interactive molecule to the surface-immobilized responsive polymer.
Figure lla shows the conjugate of a responsive copolymer and an enzyme, where the responsive copolymer has pendant drug molecules 10 conjugated to the copolymer chain backbone by linkages that are degradable by the same el~y,l,e to which the copolymer is conjugated.
When the polymer is stim~ tto(l to collapse its coil, the enzyme is turned off, and it cannot release the drug by enzymolysis of the ~clldalll linkages;
when the reverse stim-lllls is applied, the enzyme becomes active and 15 releases drug molecules by enzymolysis of the pendant linkages. A
hydrogel, with an enzyme entrapped within the gel is shown in Figure 11.
Figure 12 is a sch~m~tir illustration of ssDNA hooks for "conjugating"
the responsive polymers to the protein.
A schPm~tir illustration is provided in Figure 16 of the use of a 20 conjugate of a stimnlll~-interactive molecule and an interactive molecule such as an enzyme, antibody, or receptor protein as an environmPnt,.l sensor. The sensor protein is protected and inactive until exposed to a stimlllllc. The interactive molecule binds to a molecule such as an analyte, toxin, inhibitor or fouling agent. The sensor is regell~.dl~d by 25 removal of the stimulus. Alternatively, as demonstrated above with the affinity switches, the binding site could contain a second stimulus-interactive molecule which upon exposure to a second stimlllllc regenerates the sensor.
The present invention will be further understood by reference to 30 the following non-limiring examples.

CA 02230~7 1998-02-26 EXAMPLE 1: Conjugation of Vinyl Sulfone-Termin~erl Poly NIPAAm to SAv Mutant.
A unique cysteine thiol group was introduced near the binding pocket of streptavidin, which has no native cysteine residues, by 5 sllbstihlting Cys for Asn at position 49, which is hydrogen-bonded to the e. .l~i..,.l carboxylate of the valeric acid hydrocarbon side-chain of biotin.
cett~ site-directed mutagenesis methods were used to create the N49C
mutant streptavidin, which places the engineered polymer conjugation site near the outer edge of the biotin-binding pocket.
The N49C site-directed streptavidin mutant was constructed by r~s~otte mutagenesis techniques, using a synthetic "core" streptavidin gene decignr-l for bacterial expression. The streptavidin gene was cut between the Kpn I and Xba I sites, and a syll~heLic cassette introducing the desired Asn to Cys codon change was subsequently ligated between the sites.
15 The N49C streptavidin mutant sequence was confirrn~cl by automated dideoxy sequencing and subclones into pET 11 (Novagen, Madison, WI) for expression in E. coli strain BL21(DE3). The over-e~LL,l-,..sed protein was refolded using protocols of Stayton, supra, with the addition of 0.5 mM DTT to m~in~,.in the thiol oxidation state.
PNIPAAm with one thiol-reactive end group/chain was syntht-si7rd in two steps. In the first step, PNIPAAm polymer with -OH end groups was ~ alcd by chain ~ldl~.r~r polyllleli~Lion using 2-lllelcaploethanol as a chain LldlLsrt:l agent and 2,2'-azoisobutyronitrile as hliLid~ol. The MW
(Mn) was measured using an osmometer to be 3800. In the second step, the -OH end groups were reacted with divinyl sulfone (5 mole % excess) in the presence of triethylamine (5 mole % excess). The polymer was recovered by precipitation in ethyl ether. The product showed characteristic vinyl sulfone peaks in the proton NMR spectrum (in d6-DMSO) at 6.21 ppm (two H = CH2 and 6.97 ppm (one H = -SO2CH=).
The conjugation of the vinyl sulfone-poly(NIPAAm) to the N49C
streptavidin was performed at pH 7.0 in PBS, with Tris(2-CA 02230~7 1998-02-26 carboxyethyl)phosphine (TCEP) as a ~ fi~le reducing agent (Burns et al., J. Or~. Chem. 56: 2648-2650 (1991)), using a large excess of polymer (molar ratio of polymel.~loL~,ll of 50:1). The polymer-protein conjugate was sep~lldted from unreacted protein by thermal precipitation 5 of the poly(NIPAAm) and the conjugate at 37~C. Characterization by GPC and polyacrylamide gel electrophoresis (SDS-PAGE) demol~.L,alt:d that all of the streptavidin purified in this l,lan~lel was conjugated to poly(NIPAAm).
The poly(NIPAAm)-streptavidin conjugate was next immobilized 10 on a biotinylated microporous membrane. Hydrophilic poly(vinylidene difluoride) (PVDF) membranes (Millipore, Bedford, MA) were first coated with polyethyleneill~ille (PEI), a primary amine-cont~ining polymer, by physical adsorption of 50 kD PEI. A biotinylated surface was then prepalcd by conjugating the N-hydroxy succinimidyl ester of 15 biotin to the PEI ~ aly amine groups. The N49C streptavidin-poly(NIPAAm) conjugate was adsorbed by affinity binding of the streptavidin to the biotinylated membrane in 100 mM phosphate buffer (pH 7.0). As controls, wild-type streptavidin and the N49C streptavidin mutant were also adsorbed at comparable loading densities (as qn~ntit~t~l 20 by 3H biotin binding to the adsorbed streptavidin surfaces) to the conjugate-coated biotinylated membranes. The 3H biotin-binding capacity of the membranes were then measured in triplicates at 4~C and 37~C. At 4~C the poly (NIPAAm) is below its 32~C phase transition temperature, and the polymer is a hydrated coil. At this tellll,elilLult:, the biotin-25 binding capacity of the N49C streptavidin conjugate on the membrane wasessentially identical to the wild-type or N49C mutant streptavidin controls.
However, a sharp decrease in the biotin-binding capacity of the conjugate on the membrane was observed when the temperature was raised to 37~C, where the polymer is a collapsed globule. The wild-type and N49C
30 streptavidin controls did not show any signific~nt temperature-dependent biotin binding capacity. An 84% drop in biotin association for the CA 02230~7 1998-02-26 conjugate was observed at 37~C relative to 4~C, while the wild-type control exhibited only a 3% drop in biotin-binding capacity at 37~C vs.
4~C.
Further evidence supporting a direct link between the control of S biotin binding and the Lelllpcldlulc:-responsive phase behavior of the conjugated poly(NIPAAm) was obtained by measuring the % blockage of biotin association as a function of tC;lllp~ldlUl~ belweell 4~C and 37~C.
Figure 10 shows the effect of telll~cldlule on the ability of the poly (NIPAAm) chain conjugated to ~Ll.,~ldvidin to block the biotin binding site 10 as it collapses (open circles), and the phase sepdldLion of free poly (NIPAAm) in ic1entir~l buffer conditions as measured by decl~asing light tr~ncmi~ion (closed circles). It can be seen that both curves decrease across the same temperature range, with nearly identi~l midpoints. The initiation of blocking activity of the conjugate precedes the sharp cloud 15 point transition of the free polymer, which likely reflects the initiation of the gradual collapse of individual poly(NIPAAm) chains at the biotin binding pockets. The free poly(NIPAAm) chains in solution, on the other hand, must reach a critical level of hydrophobicity as they release bound water, at which condition they will aggregate together and ple.;i~iLaLe, 20 which leads to a cooperative phase ~ aldLion and the observed sharp reduction in light Ll~ n. The initial collapse of the poly(NIPAAm) chains that precedes the critical aggregation point can be seen in the activity assay for the conjugate as the early blocking of biotin binding around 20-25~C (which is well below the LCST of the free polymer in 25 solution).
Thus, these results demonstrate that the blocking of streptavidin-biotin association directly correlates with the collapse of the poly(NIPAAm) random coil, jnrli-~ting that the affinity recognition process is indeed being controlled by narrow environmental control of the 30 size of the polymer coil conjugated specifically at the N49C streptavidin binding pocket. The site-specific conjugation of such phase reversible CA 02230~7 1998-02-26 polymers to gen.otiç~lly-engineered recognition proteins thus provides very sensitive euvin~lllllental control of the ligand-protein recognition process.
li'Y~mple 2: r~ardlion of a tempelaLule-s~l~silive chain with two reactive end groups.
PNIPAAm with two carboxyl terminal groups can be synth.o-~i7.
by using a two-component h~irelLel system. The chemistry, shown in Figure 13, was developed as described in: Otsu, T., et al. (1992) Eur.
Polym. J.. 28, 1325-1329. In the system, 4,4-a_obis4-cyanovaleric acid (ABCVA) was used as an initiator and 3,3'-dithiodipropionic acid 10 (DTDPA) was used as a chain tldl~r~. agent.
N-isopropylacrylamide (NIPAAm, F~ctm~n Kodak, Rochester, NY, USA) was purified by recrysf~lli7~tion from n-hexane. ABCVA
(PFATZ & BAUER INC.) and DTDPA (Aldrich) were used as received.
11.3 g of monomer, NIPAAm, plus 0.1 mole% ABCVA and 5 15 mole% DADPA were dissolved in 50 ml of DMF. The solution was degassed by fi~,e~illg and ev~ ting and thawing three times and then sealed. Polymerization was carried out at 60~C for 3 hours. The polymer was collected by ~,lecil.iL~Lion in diethyl ether and dried in vacuum. The molecular weight of the polymer was ~lel~,l...i..~(1 by vapor pressure osmometry (VPO, model OSVlll from Knauer, German) and the content of carboxyl groups of the polymer was determined by back titration.
FY~mple 3: Synthesis of a pH- and t~ dlule-se~silive polymer and its LCST behavior at two pHs.
N-isopropylacrylamide (NIPAAm, F~ctm~n Kodak, Rochester, USA) was purified by recryst~lli7~rion from n-hexane and dried in vacuum. Dimethylform~mi~e (DMF) and 2-mercapthoethanol (ME) were used without further purification. Acrylic acid (AAc, Aldrich, Milwaukee, USA) was redistilled in vacuo before use. 2-2' A_oisobu~yloluLlile (AIBN, J.T. Baker, Phillisburg, USA) was CA 02230~7 1998-02-26 ~e~;"~ 11i7~d from m.oth~n~h All other reagents used were of analytical grade.
Poly(NIPAAm/AAc) with a terminal hydroxyl group was synth~si7P~I by chain Lldll~L~l free radical copolymerization of NIPAAm (16.95 g, 150 mmol) and AAc (0.108 g, 1.5 mmol) in DMF (60 ml) at 60~C for 20 min using a chain L,dl~rer agent, ME (0.478 g, 6 mrnol) and a free radical initiator, AIBN (0.246 G, l.5 mmol). Product was obtained by pleci~.iL~Lillg the reaction solution into diethyl ether, filtered through a sintered glass filter, washed repeatedly with diethyl ether, and dried in vacuum at 40~C for 24 h.
The synthesis is shown in Figure 14.
The t~npt,.dLulc~ and pH sel~iiLiv~ behaviors of copolymer were studied by spectopholulll.,Llically deL~ .i..i..g the turbidity of the polymer solution (2.0 mg/ml) at various tt~ JcldLuies and pHs at a fixed wavelength (500 nm). Citric-phosphate buffers were employed for invesfig~ting the effect of pH on the lelllp~dLUl~ sel~iLiv~ behaviors of the copolymer. Ionic strength of the buffer solutions was adjusted by adding NaCl. The Lelll~eldlult at 10% absorbance of the polymer solution was defined as the LCST.
Figure lS shows the absoll,allce vs lt~ elalule of 0.2% solution of poly (NIPAAm/AAc) in citric+phosphate buffers at pH 4.0 and 7.4.
Ionic ~LlcllgLlls of buffer solutions were adjusted by adding NaCl. Molar ratios of NIPAAm/AAc/2-MElaibn: lO0/1/4/l, polym~ori7~tion time: 20 min, pol~nreli~alion telllpeldLLIre: 60~C.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of underst~n-ling, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

Claims (31)

We claim:
1. A stimulus responsive molecule comprising:
an affinity interactive region capable of specifically binding to a target; and a stimulus responsive region capable of modulating the binding of the affinity interactive region to the target in response to a stimulus;
wherein the stimulus responsive molecule is not a naturally occurring allosteric enzyme.
2. The stimulus responsive molecule of claim 1 wherein the stimulus responsive region is capable of modulating the binding of the affinity interactive region to the target in response to a stimulus selected from the group consisting of temperature, light, pH, specific ions, ionic strength, electric field and solvents.
3. The stimulus responsive molecule of claim 1 wherein the affinity interactive region is selected from the group consisting of a protein, peptide, polysaccharide, oligosaccharide, nucleic acid, glycoprotein, lipid and synthetic receptor or ligand.
4. The stimulus responsive molecule of claim 1 wherein the affinity interactive region is selected from the group consisting of an antibody, antigen, cell membrane receptor, a ligand capable of binding to a cell membrane receptor, an enzyme, an enzyme substrate, and a cofactor.
5. The stimulus responsive molecule of claim 1 wherein the target is selected from the group consisting of an antibody, antigen, cell membrane receptor, a ligand capable of binding to a cell membrane receptor, an enzyme, an enzyme substrate, and a cofactor.
6. The stimulus responsive molecule of claim 1 wherein the affinity interactive region comprises a therapeutic agent, a diagnostic agent, or a catalytic agent.
7. The stimulus responsive molecule of claim 1 wherein the affinity interactive region comprises a therapeutic agent selected from the group consisting of an antibiotic agent, an antiinflammatory agent, an anti-cancer agent, an anti-viral agent and an anti-enzyme agent.
8. The stimulus responsive molecule of claim 1 wherein the stimulus responsive molecule is immobilized upon a surface or within a hydrogel.
9. The stimulus responsive molecule of claim 1 comprising a spacer between the affinity interactive region and the stimulus responsive region.
10. A method for making a stimulus responsive molecule comprising:
covalently linking an affinity interactive region capable of specifically binding to a target with a stimulus responsive region capable of modulating the binding of the affinity interactive region to the target in response to a stimulus;
wherein the stimulus responsive molecule is not a naturally occurring allosteric enzyme.
11. The method of claim 10 wherein the stimulus responsive region is capable of modulating the binding of the affinity interactive region to the target in response to a stimulus selected from the group consisting of temperature, light, pH, specific ions, ionic strength, electric field and solvents.
12. The method of claim 10 wherein the affinity interactive region is selected from the group consisting of a protein, peptide, polysaccharide, oligosaccharide, nucleic acid, glycoprotein, lipid and receptor or ligand.
13. The method of claim 10 wherein the affinity interactive region is selected from the group consisting of an antibody, antigen, cell membrane receptor, a ligand capable of binding to a cell membrane receptor, an enzyme, an enzyme substrate and a cofactor.
14. The method of claim 10 wherein the target is selected from the group consisting of an antibody, antigen, cell membrane receptor, a ligand capable of binding to a cell membrane receptor, an enzyme, and an enzyme substrate and a cofactor.
15. The method of claim 10 wherein the affinity interactive region comprises a therapeutic agent, a diagnostic agent, or a catalytic agent.
16. The method of claim 10 wherein the affinity interactive region comprises a therapeutic agent selected from the group consisting of an antibiotic agent, an anti-inflammatory agent, a catalytic agent, an anti-cancer agent, an anti-viral agent, and an anti-enzyme agent.
17. The method of claim 10 wherein the target comprises a therapeutic agent, a diagnostic agent, or a catalytic agent.
18. The method of claim 10 wherein the stimulus responsive molecule is immobilized upon a surface or within a hydrogel.
19. The method of claim 18 wherein the stimulus responsive molecule is immobilized on a solid surface and wherein the method further comprises separating the target from a mixture using the stimulus responsive molecule in a separation method selected from the group consisting of low pressure chromatography, high performance liquid chromatography, affinity precipitation, membrane separation, two phase separation and immunoadsorption separation.
20. The method of claim 18 wherein the stimulus responsive molecule immobilized upon a surface is provided within a sensor device for the detection of the target, the method further comprising detecting the target in a sample with the sensor.
21. Use of the stimulus responsive molecule of claim 1 in a method of separating a target from a mixture, the method comprising:
i) contacting the mixture with the stimulus responsive molecule;
ii) permitting the target to bind to the affinity interactive region of the stimulus responsive molecule, thereby to isolate and separate the target from other components in the mixture; and iii) subjecting the bound target to conditions which cause the target to be released from the stimulus responsive molecule.
22. The use of claim 21 wherein the stimulus responsive region is capable of enhancing or reducing the affinity of binding of the target to the affinity interactive region in response to the stimulus.
23. The use of claim 21 wherein step iii) comprises applying a stimulus to the stimulus responsive region to thereby reduce the affinity of binding of the target to the affinity interactive region and to cause the targetto be released.
24. The use of claim 21 wherein the stimulus responsive molecule is immobilized on a solid surface, and wherein the method comprises separating the target from a mixture in a process selected from the group consisting of low pressure chromatography, high performance liquid chromatography, affinity precipitation, membrane separation, two phase separation and immunoadsorption separation.
25. The use of the stimulus responsive molecule of claim 1 in a method for detecting a target in a sample, the method comprising:
i) contacting the sample with the stimulus responsive molecule;
ii) permitting the target to bind to the affinity interactive region; and iii) detecting the binding of the target to the affinity interactive region.
26. The use of claim 25 wherein the binding of the target to the affinity interactive region is detected by detecting a labeled monoclonal antibody bound to the target which is bound to the affinity interactive region.
27. The use of claim 26 wherein the affinity interactive region comprises streptavidin, and wherein in step ii) the streptavidin binds to a biotinylated monoclonal antibody which is bound to the target, and wherein the target further is bound to the labeled monoclonal antibody.
28. The use of claim 25 wherein the target is an environmental toxin.
29. The use of claim 25 wherein the method further comprises quantitating the amount of the target in the sample.
30. The use of the stimulus responsive molecule of claim 1, wherein the target is a therapeutic agent, in a method for delivering a drug to a patient, the method comprising:
i) complexing the target consisting of a therapeutic agent with the affinity interactive region of the stimulus responsive molecule;
ii) administering the complex of the target consisting of a therapeutic agent and the stimulus responsive molecule to a patient in need of the therapeutic agent; and iii) stimulating the complex in the patient to cause the release of the target in the patient.
31. The use of claim 30 wherein the complex is administered intravenously.
CA002230557A 1995-09-01 1996-08-30 Interactive molecular conjugates Abandoned CA2230557A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US314895P 1995-09-01 1995-09-01
US60/003,148 1995-09-01

Publications (1)

Publication Number Publication Date
CA2230557A1 true CA2230557A1 (en) 1997-03-13

Family

ID=21704411

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002230557A Abandoned CA2230557A1 (en) 1995-09-01 1996-08-30 Interactive molecular conjugates

Country Status (8)

Country Link
US (1) US5998588A (en)
EP (1) EP0851768B1 (en)
JP (1) JP2000500733A (en)
AT (1) ATE216594T1 (en)
AU (1) AU716154B2 (en)
CA (1) CA2230557A1 (en)
DE (1) DE69620898T2 (en)
WO (1) WO1997009068A2 (en)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
EP0986402A2 (en) 1997-06-06 2000-03-22 Battelle Memorial Institute Reversible geling co-polymer and method of making
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
AU2002301047B2 (en) * 1997-06-20 2005-11-10 Ciphergen Biosystems, Inc. Retentate Chromatography And Protein Chip Arrays With Applications In Biology And Medicine
EP0922715B8 (en) * 1997-12-09 2008-05-21 National Institute of Advanced Industrial Science and Technology Stimuli-responsive polymer utilizing keto-enol tautomerization
GB9726888D0 (en) * 1997-12-20 1998-02-18 Eev Ltd Detection
EP2138191A1 (en) * 1998-01-05 2009-12-30 University Of Washington Enhanced transport using membrane disruptive agents
US6296831B1 (en) 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
EP1006362A1 (en) * 1998-12-02 2000-06-07 Michael Dr. Cahill Method and apparatus for the separation of components from a biological material
AU3867400A (en) * 1999-03-19 2000-10-09 Duke University Methods of using bioelastomers
GB9923146D0 (en) * 1999-09-30 1999-12-01 Imperial College Detector array
US6258275B1 (en) * 1999-10-01 2001-07-10 Ecole Polytechnique Federale De Lausanne Affinity macroligands
ATE427743T1 (en) 1999-11-15 2009-04-15 Biocure Inc POLYMERIC HOLLOW PARTICLES RESPONSIVE TO EXTRAORDINARY CONDITIONS
US7737108B1 (en) * 2000-01-07 2010-06-15 University Of Washington Enhanced transport using membrane disruptive agents
US7163712B2 (en) * 2000-03-03 2007-01-16 Duke University Microstamping activated polymer surfaces
US6444254B1 (en) 2000-03-03 2002-09-03 Duke University Microstamping activated polymer surfaces
US20040134846A1 (en) * 2000-04-05 2004-07-15 Yoshikatsu Akiyama Novel material for use in separation and separating method using the same
US6660247B1 (en) * 2000-06-23 2003-12-09 Battelle Memorial Institute Multiple stimulus reversible hydrogels
US20020022266A1 (en) * 2000-06-28 2002-02-21 Wagner William R. Localized delivery to a target surface
EP1227321A1 (en) * 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
JP4797143B2 (en) * 2001-01-31 2011-10-19 独立行政法人産業技術総合研究所 Catalytic reaction control method
EP1373868B1 (en) 2001-02-01 2015-05-20 Sigma-Aldrich Co. LLC Improved affinity matrices with enhanced visibility for molecular pull-down and immunoprecipitation applications
WO2003012423A1 (en) * 2001-07-31 2003-02-13 Mitsubishi Rayon Co., Ltd. Hollow fiber having inner wall into which comb polymer is introduced, hollow fiber impregnated with gel, and fiber array thin section
US7456025B2 (en) * 2001-08-28 2008-11-25 Porex Corporation Sintered polymer membrane for analyte detection device
US20030108972A1 (en) * 2001-12-06 2003-06-12 Zweig Stephen Eliot Tethered receptor-ligand reagent and assay
US20040241173A1 (en) * 2002-02-14 2004-12-02 William Marsh Rice University Fullerene (C60) vancomycin conjugates as improved antibiotics
DE10224352A1 (en) * 2002-06-01 2003-12-11 Mueller Schulte Detlef Thermosensitive polymer carrier with changeable physical structure for biochemical analysis, diagnostics and therapy
AU2003254092A1 (en) * 2002-07-19 2004-02-09 Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University Localized delivery system for phenstatin using n-isopropylacrylamide
CA2497273C (en) 2002-07-29 2014-06-10 Mt Technologies, Inc. Biomimetic membranes
CN100377766C (en) * 2002-07-29 2008-04-02 Mt技术股份有限公司 Biomimetic membranes
US20040062882A1 (en) * 2002-09-30 2004-04-01 Andrea Liebmann-Vinson Cell adhesion resisting surfaces
WO2004044139A2 (en) 2002-11-05 2004-05-27 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
WO2004044141A2 (en) * 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Conjugated oligomeric compounds and their use in gene modulation
AU2002953073A0 (en) * 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
TWI354021B (en) * 2002-12-23 2011-12-11 Alcon Inc Compositions and methods for inhibiting protein on
US7083948B1 (en) 2002-12-24 2006-08-01 Immunex Corporation Polypeptide purification reagents and methods for their use
TWI257928B (en) * 2002-12-27 2006-07-11 Ind Tech Res Inst Method for the separation of polysaccharides
EP1631375B1 (en) 2003-01-17 2011-11-02 Cornell Research Foundation, Inc. Injectable hydrogel microspheres from aqueous two-phase system
US7695752B2 (en) 2003-01-24 2010-04-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target activated microtransfer
CA2513646C (en) * 2003-01-24 2013-09-17 Michael R. Emmert-Buck Target activated microtransfer
AU2004210964A1 (en) * 2003-02-11 2004-08-26 University Of Washington Stimuli-responsive polymer conjugates and related methods
SE0300791D0 (en) * 2003-03-20 2003-03-20 Amersham Biosciences Ab Use of ph-responsive polymers
WO2005039641A2 (en) * 2003-10-15 2005-05-06 The Regents Of The University Of California Biomacromolecule polymer conjugates
DE10350248A1 (en) * 2003-10-28 2005-06-16 Magnamedics Gmbh Thermosensitive, biocompatible polymer carriers with variable physical structure for therapy, diagnostics and analytics
US20050096446A1 (en) * 2003-10-29 2005-05-05 Council Of Scientific And Industrial Tri-block copolymers and a process for the preparation of the same
WO2005044309A1 (en) * 2003-11-05 2005-05-19 Photobiomed Corporation Bonding tissues and cross-linking proteins with naphthalimide compounds
WO2005064338A1 (en) * 2003-12-23 2005-07-14 University Of Florida Research Foundation, Inc. Microparticles for use in diagnostic methods
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
GB0412631D0 (en) * 2004-06-07 2004-07-07 Cambridge Applied Polymers Ltd Polymer release system
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
EP1804579A1 (en) * 2004-10-18 2007-07-11 E.I. Dupont De Nemours And Company Process for making antimicrobial polymer articles
JP2006158305A (en) * 2004-12-08 2006-06-22 National Institute Of Advanced Industrial & Technology Adsorbent for separating cell, adsorbent module for separating cell and method for separating cell
EP1850858A2 (en) * 2005-02-10 2007-11-07 Emory University Polyethylene oxide polymers including anti-inflammatory glycodendrons
US8157807B2 (en) 2005-06-02 2012-04-17 The Invention Science Fund I, Llc Skin treatment including patterned light
JP2006312117A (en) * 2005-05-06 2006-11-16 Canon Inc Separation material for physiologically active substance and its production method
GB0515625D0 (en) * 2005-07-29 2005-09-07 Univ Manchester Hydrogel particle
JP2007071832A (en) * 2005-09-09 2007-03-22 Shiseido Co Ltd Modified gold particles
US7957466B2 (en) * 2005-09-16 2011-06-07 Sony Corporation Adaptive area of influence filter for moving object boundaries
US8114843B2 (en) 2005-11-18 2012-02-14 The Regents Of The University Of California Photoreactive regulator of protein function and methods of use thereof
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US7709227B2 (en) * 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
US7718193B2 (en) * 2006-03-16 2010-05-18 University Of Washington Temperature- and pH-responsive polymer compositions
FR2902799B1 (en) 2006-06-27 2012-10-26 Millipore Corp METHOD AND UNIT FOR PREPARING A SAMPLE FOR THE MICROBIOLOGICAL ANALYSIS OF A LIQUID
US8815518B2 (en) 2006-06-30 2014-08-26 Jnc Corporation Kit for detection/quantification of analyte, and method for detection/quantification of analyte
US8362217B2 (en) * 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) * 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US7981688B2 (en) 2007-03-08 2011-07-19 University Of Washington Stimuli-responsive magnetic nanoparticles and related methods
US20100151465A1 (en) 2008-03-27 2010-06-17 Jingyue Ju Selective Capture and Release of Analytes
SI2220107T1 (en) 2007-11-12 2017-02-28 Chreto Aps Dual affinity polypeptides for purification
CA2710681C (en) 2007-12-28 2013-09-03 Ortho-Clinical Diagnostics Kabushiki Kaisha Detection method and determination method for detection target
WO2009084595A1 (en) 2007-12-28 2009-07-09 Ortho-Clinical Diagnostics Kabushiki Kaisha Method of detecting substance to be detected and method of determination
US8999702B2 (en) * 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
CA2953975C (en) 2008-06-27 2019-11-26 Duke University Therapeutic agents comprising elastin-like peptides
AU2009301502B2 (en) * 2008-10-07 2013-05-30 Applied Biomimetic A/S Biomimetic membrane formed from a vesicle-thread conjugate
US20100150952A1 (en) * 2008-11-07 2010-06-17 University Of Washington pH-RESPONSIVE POLYMER CARRIER COMPOSITIONS FOR CYTOSOLIC PROTEIN DELIVERY
CN105037535A (en) 2008-12-16 2015-11-11 Emd密理博公司 Stirred tank reactor and method
US9041541B2 (en) 2010-01-28 2015-05-26 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
US9033898B2 (en) 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
WO2010101625A2 (en) 2009-03-02 2010-09-10 Seventh Sense Biosystems, Inc. Oxygen sensor
WO2012018486A2 (en) 2010-07-26 2012-02-09 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
US20120277629A1 (en) 2011-04-29 2012-11-01 Seventh Sense Biosystems, Inc. Systems and methods for collection and/or manipulation of blood spots or other bodily fluids
EP2408372B1 (en) 2009-03-02 2019-01-09 Seventh Sense Biosystems, Inc. Devices associated with blood sampling
US9090663B2 (en) * 2009-04-21 2015-07-28 The Trustees Of Columbia University In The City Of New York Systems and methods for the capture and separation of microparticles
WO2010137532A1 (en) * 2009-05-29 2010-12-02 チッソ株式会社 Detection method and quantification method of detection target
US8426214B2 (en) * 2009-06-12 2013-04-23 University Of Washington System and method for magnetically concentrating and detecting biomarkers
KR101943420B1 (en) 2009-08-14 2019-04-17 파세비오 파마수티컬스 인코포레이티드 Modified Vasoactive Intestinal Peptide
US9080933B2 (en) 2009-11-09 2015-07-14 University Of Washington Through Its Center For Commercialization Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates
JP2013509963A (en) 2009-11-09 2013-03-21 スポットライト テクノロジー パートナーズ エルエルシー Fragmented hydrogel
CN102695500A (en) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 Polysaccharide based hydrogels
US20110117668A1 (en) * 2009-11-09 2011-05-19 University Of Washington Through Its Center For Commercialization Self-powered smart diagnostic devices
EP2571903B1 (en) * 2010-05-17 2019-09-04 EMD Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
US20120016308A1 (en) 2010-07-16 2012-01-19 Seventh Sense Biosystems, Inc. Low-pressure packaging for fluid devices
US20120039809A1 (en) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systems and techniques for monitoring subjects
WO2012064802A1 (en) 2010-11-09 2012-05-18 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
US8298298B1 (en) 2010-12-22 2012-10-30 Empire Development Technology LLC Dyes with changeable solubilities, and methods for their use
US8246698B2 (en) 2010-12-22 2012-08-21 Empire Technology Development Llc Dyes with changeable solubilities, and methods for their use
ES2597081T3 (en) 2011-04-29 2017-01-13 Seventh Sense Biosystems, Inc. Delivery and / or reception of fluids
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
WO2013019714A1 (en) 2011-07-29 2013-02-07 The Trustees Of Columbia University In The City Of New York Mems affinity sensor for continuous monitoring of analytes
TWI425096B (en) * 2012-02-10 2014-02-01 Nat Applied Res Laboratories Modifying surface of a substrate with bio-molecules
DK2857420T3 (en) 2012-05-30 2020-11-23 Chugai Pharmaceutical Co Ltd TARGET TISSUE SPECIFIC ANTIGIN BINDING MOLECULE
WO2014121802A1 (en) * 2013-02-07 2014-08-14 Zaghloul Mohammad Hosam Eldeen Innovative nano-elisa single test for the detection of hcv, hiv antibodies and hbsag
WO2014176279A1 (en) * 2013-04-22 2014-10-30 Carnegie Mellon Iniversity Polymer-based protein engineering methods to rationally tune enzyme activity, ph-dependence and stability
US10359419B2 (en) * 2013-10-02 2019-07-23 General Electric Company Methods for detection of target using affinity binding
US20150093839A1 (en) * 2013-10-02 2015-04-02 General Electric Company Methods and systems for detection of target and applications thereof
SG11201604495PA (en) 2013-12-04 2016-07-28 Chugai Pharmaceutical Co Ltd Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
CA2947982C (en) 2014-05-08 2022-11-29 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
WO2016022696A1 (en) 2014-08-05 2016-02-11 The Trustees Of Columbia University In The City Of New York Method of isolating aptamers for minimal residual disease detection
AU2016219513B2 (en) 2015-02-09 2021-09-30 Immunoforge Co., Ltd. Methods and compositions for treating muscle disease and disorders
JP6778380B2 (en) 2016-08-23 2020-11-04 昭和電工マテリアルズ株式会社 Adsorbent
GB201615989D0 (en) * 2016-09-20 2016-11-02 Imp Innovations Ltd Drug Delivery
DE102016119102A1 (en) 2016-10-07 2018-04-12 Forschungszentrum Jülich GmbH Translocation of synthetic polymers through lipid membranes
KR20230132603A (en) 2017-01-11 2023-09-15 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 antagonists and uses thereof
EP3595720A4 (en) 2017-03-14 2021-05-26 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
WO2018185503A1 (en) 2017-04-07 2018-10-11 The University Of Birmingham Stimuli-responsive surfaces
US10450345B2 (en) * 2017-06-09 2019-10-22 General Electric Company Method of isolation of polypeptide-aptamer-polymer conjugates
US11472894B2 (en) 2018-07-23 2022-10-18 Carnegie Mellon University Enzyme-assisted ATRP procedures
JP2020020719A (en) * 2018-08-02 2020-02-06 キヤノンメディカルシステムズ株式会社 Analytic method, reagent kit, and analyzer
WO2021078813A1 (en) * 2019-10-21 2021-04-29 Mip Diagnostics Limited Thermally responsive conjugates

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843010A (en) * 1983-11-10 1989-06-27 Genetic Systems Corporation Polymerization-induced separation immunoassays
US4752638A (en) * 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
US4609707A (en) * 1983-11-10 1986-09-02 Genetic Systems Corporation Synthesis of polymers containing integral antibodies
GB8423228D0 (en) * 1984-09-14 1984-10-17 Unilever Plc Specific binding materials
DE3583940D1 (en) * 1984-10-02 1991-10-02 Harry M Meade PRODUCTION OF STREPTAVIDINE-LIKE POLYPEPTIDES.
US4780409A (en) * 1985-05-02 1988-10-25 Genetic Systems Corporation Thermally induced phase separation immunoassay
JPS61265090A (en) * 1985-05-17 1986-11-22 Tanabe Seiyaku Co Ltd Reversely soluble immobilized enzyme
US4839293A (en) * 1986-02-24 1989-06-13 The Trustees Of Columbia University In The City Of New York DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4971905A (en) * 1987-08-11 1990-11-20 Pacific Northwest Research Foundation Diagnosis of cancerous or precancerous conditions in human secretory epithelia by enzyme activity of β-1-3N-acetylglucosaminyltransferase
US5135876A (en) * 1987-09-24 1992-08-04 University Of Utah Method and apparatus for the regulation of complex binding
US5013669A (en) * 1988-06-01 1991-05-07 Smithkline Diagnostics, Inc. Mass producible biologically active solid phase devices
US5112770A (en) * 1988-06-08 1992-05-12 North Carolina State University Precipitation of multivalent antiligands with affinity surfactants
JPH0383914A (en) * 1989-08-18 1991-04-09 W R Grace & Co Drug carrier
EP0469681B1 (en) * 1990-08-03 1994-10-12 Koninklijke Philips Electronics N.V. Optical amplifier
EP0470681A3 (en) * 1990-08-08 1992-04-22 W.R. Grace & Co.-Conn. Cell clusters or sheets comprising a plurality of cell species and preparations thereof
US5226902A (en) * 1991-07-30 1993-07-13 University Of Utah Pulsatile drug delivery device using stimuli sensitive hydrogel
US5417983A (en) * 1992-02-19 1995-05-23 Sagami Chemical Research Center Drug release controlling material responsive to changes in temperature
US5753261A (en) * 1993-02-12 1998-05-19 Access Pharmaceuticals, Inc. Lipid-coated condensed-phase microparticle composition

Also Published As

Publication number Publication date
AU7011096A (en) 1997-03-27
JP2000500733A (en) 2000-01-25
EP0851768A2 (en) 1998-07-08
EP0851768B1 (en) 2002-04-24
DE69620898D1 (en) 2002-05-29
DE69620898T2 (en) 2002-11-07
ATE216594T1 (en) 2002-05-15
US5998588A (en) 1999-12-07
WO1997009068A3 (en) 1997-08-28
WO1997009068A2 (en) 1997-03-13
AU716154B2 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
CA2230557A1 (en) Interactive molecular conjugates
US7625764B2 (en) Stimuli-responsive polymer devices
Sivaram et al. Recent advances in the generation of antibody–nanomaterial conjugates
Shen et al. Site-selective orientated immobilization of antibodies and conjugates for immunodiagnostics development
Chen et al. Molecular imprinting: perspectives and applications
EP0701697B1 (en) Coating of hydrophobic surfaces to render them protein resistant while permitting covalent attachment of specific ligands
Gedig Surface chemistry in SPR technology
Hoffman et al. Bioconjugates of smart polymers and proteins: synthesis and applications
Balthasar et al. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes
Ding et al. Synthesis and purification of thermally sensitive oligomer− enzyme conjugates of poly (N-isopropylacrylamide)− trypsin
Vega et al. Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly (L-glutamic acid) through a polyethylene glycol spacer
US20110003392A1 (en) System and Method for Magnetically Concentrating and Detecting Biomarkers
EP1696235B1 (en) Biosensor
Nagase et al. Temperature-responsive chromatography for bioseparations: A review
Choi et al. The role of ligand–receptor interactions in visual detection of HepG2 cells using a liquid crystal microdroplet-based biosensor
CN105492030A (en) Stimuli-responsive magnetic nanoparticles
Nehilla et al. A stimuli-responsive, binary reagent system for rapid isolation of protein biomarkers
Ji et al. Increased sensitivity in antigen detection with fluorescent latex nanosphere− IgG antibody conjugates
Chou et al. Glycan-Directed Grafting-from Polymerization of Immunoglobulin G: Site-Selectively Modified IgG–Polymer Conjugates with Preserved Biological Activity
EP1391730A1 (en) Biopolymer-containing gel
JP2006177914A (en) Surface having thick polymer layer, and preparation method therefor
Rathi et al. Biorecognition of sugar containing N‐(2‐hydroxypropyl) methacrylamide copolymers by immobilized lectin
Ebara et al. Smart Bioconjugates
Kamzabek et al. Thermoresponsive Fluorescence Switches Based on Au@ pNIPAM Nanoparticles
CA2970845A1 (en) Macromolecular conjugates for isolation, immobilization and visualization of proteins

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued